content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">As filed with the Securities and Exchange Commission
  on July 13, 2021</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Registration No. 333-________</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>UNITED STATES</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>SECURITIES AND
  EXCHANGE COMMISSION</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Washington, D.C.
  20549</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>FORM S-8</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
  ACT OF 1933</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 24pt"><B>Alzamend Neuro,
  Inc.</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 54%">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>Delaware</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center">(State or other jurisdiction of</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center">incorporation or organization)</P></TD>
      <TD STYLE="width: 46%">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>81-1822909</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center">(I.R.S. Employer</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center">Identification No.)</P></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3802 Spectrum Boulevard, Suite 112C<BR>
  Tampa, Florida 33612</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of Principal Executive Offices) (Zip Code)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2016 Amended and Restated Stock Incentive Plan</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2021 Stock Incentive Plan</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Option Award Agreements</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Full title of the plans)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Stephan Jackman, Chief Executive Officer</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Alzamend Neuro, Inc.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3802 Spectrum Boulevard, Suite 112C</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tampa, Florida 33612</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name and address of agent for service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(844) 722-6333</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Telephone number, including area code, of agent
  for service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">It is requested that copies of notices and communications
  from the Securities and Exchange Commission be sent to:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 1%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&NegativeThickSpace;</FONT></TD>
      <TD STYLE="width: 42%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spencer G. Feldman, Esq.<BR>
  Kenneth A. Schlesinger, Esq.<BR>
  Olshan Frome Wolosky LLP<BR>
  1325 Avenue of the Americas, 15th&nbsp;Floor<BR>
  New York, NY 10019<BR>
  Tel.: (212) 451-2300</FONT></TD>
      <TD STYLE="width: 11%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&NegativeThickSpace;</FONT></TD>
      <TD STYLE="width: 46%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Henry C.W. Nisser, Esq.<BR>
  Executive Vice President &amp; General Counsel<BR>
  Alzamend Neuro, Inc.<BR>
  100 Park Avenue, Suite 1658<BR>
  New York, NY 10017<BR>
  Tel.: (646) 650-5044</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
  See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
  and &ldquo;emerging growth company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 3%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 57%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large&nbsp;accelerated&nbsp;filer&nbsp;</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
      <TD STYLE="width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated&nbsp;filer&nbsp;</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
      </TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      </TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated&nbsp;filer&nbsp;</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller&nbsp;reporting&nbsp;company&nbsp;</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
      </TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&NegativeThickSpace;</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging&nbsp;growth&nbsp;company&nbsp;</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
      </TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If an emerging
  growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
  new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act. </FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 34%; border-bottom: black 1.5pt solid">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>Title of Securities</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>to be Registered</B></P></TD>
      <TD STYLE="white-space: nowrap; width: 1%; border-bottom: black 1.5pt solid">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 12%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount to be <BR>
  Registered (1)</B></FONT></TD>
      <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%; border-bottom: black 1.5pt solid">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 16%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed <BR>
  Maximum Offering <BR>
  Price Per Share </B></FONT></TD>
      <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%; border-bottom: black 1.5pt solid">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 16%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed <BR>
  Maximum <BR>
  Aggregate Offering <BR>
  Price</B></FONT></TD>
      <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%; border-bottom: black 1.5pt solid">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 15%; border-bottom: black 1.5pt solid">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.6pt 0pt 0; text-align: center"><B>Amount of</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.6pt 0pt 0; text-align: center"><B>Registration Fee</B></P></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.0001 par value</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,550,000 (2)</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.78 (3)</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$15,249,000</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,663.67</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.0001 par value</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">500,000 (5)</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$6.18 (6)</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3,090,000</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$337.12</FONT></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.0001 par value</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,900,000 (7)</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.70 (3)</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10,030,000</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,094.27</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.0001 par value</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">450,000 (8)</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$6.18 (6)</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,781,000</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$303.41</FONT></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.0001 par value</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,500,000 (9)</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$6.18 (6)</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$58,710,000</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$6,405.26</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL</B></FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>35,900,000</B></FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$89,860,000</B></FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$9,803.73</B></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
      <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Registration Statement also registers an indeterminable number of additional securities to be offered or issued upon adjustments or changes made to registered securities by reason of any stock splits, stock dividends or similar transactions as permitted by Rule 416(a) and Rule 416(b) under the Securities Act of 1933, as amended, or the Securities Act.</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents shares of common stock issuable pursuant to stock option awards outstanding under the 2016 Amended and Restated Stock Incentive Plan (the &ldquo;<B>2016 Plan</B>&rdquo;).</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated pursuant to Rule 457(h) solely for purposes of calculating the aggregate offering price and the amount of the registration fee based upon a weighted average of the exercise prices of outstanding options previously granted.</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents shares of common stock issuable pursuant to stock option awards outstanding under the 2021 Stock Incentive Plan (the &ldquo;<B>2021 Plan</B>&rdquo;).</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents shares of restricted stock issued upon settlement of restricted stock units issued under the 2021 Plan.</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated pursuant to Rule 457(c) and (h) solely for purposes of calculating the aggregate offering price and the amount of the registration fee based upon the average of the high and low prices reported for the shares on The Nasdaq Capital Market on July 8, 2021.</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents shares of common stock issuable pursuant to stock option agreements outside of the 2016 Plan and 2021 Plan.</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents shares of common stock reserved for future issuance pursuant to the 2016 Plan.</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents shares of common stock reserved for future issuance pursuant to the 2021 Plan.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement on Form S-8 (this
  &ldquo;<B>Registration Statement</B>&rdquo;) is being filed by Alzamend Neuro, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;),
  relating to (i) 19,550,000 shares of common stock, par value $0.0001 per share (the &ldquo;<B>Common Stock</B>&rdquo;), issuable upon
  the exercise of stock options granted under the Alzamend Neuro, Inc. 2016 Amended and Restated Stock Incentive Plan (the &ldquo;<B>2016
  Plan</B>&rdquo;); (ii) 500,000 restricted shares of Common Stock issued under the Alzamend Neuro, Inc. 2021 Stock Incentive Plan (the
  &ldquo;<B>2021 Plan</B>&rdquo;); (iii) 450,000 shares of Common Stock available for issuance under the 2016 Plan; (iv) 9,500,000 shares
  of Common Stock available for issuance under the 2021 Plan; and (v) 5,900,000 shares of Common Stock issuable upon the exercise of stock
  options granted to certain employees pursuant to option agreements outside of the 2016 Plan and 2021 Plan (the &ldquo;<B>Option Agreements</B>&rdquo;,
  and together with the 2016 Plan and the 2021 Plan, the &ldquo;<B>Plans</B>&rdquo;).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement also includes a prospectus
  (the &ldquo;<B>Reoffer Prospectus</B>&rdquo;) prepared in accordance with General Instruction C of Form S-8 and in accordance with the
  requirements of Part I of Form S-3. This Reoffer Prospectus may be used for the reoffer and resale of shares of Common Stock on a continuous
  or delayed basis that may be deemed to be &ldquo;restricted securities&rdquo; and/or &ldquo;control securities&rdquo; within the meaning
  of the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), and the rules and regulations promulgated thereunder,
  that are issuable to certain of our executive officers, employees, consultants and directors identified in the Reoffer Prospectus. The
  number of shares of Common Stock included in the Reoffer Prospectus represents shares of Common Stock issuable to the selling stockholders
  pursuant to equity awards, including stock options and restricted stock grants, granted to the selling stockholders and does not necessarily
  represent a present intention to sell any or all such shares of Common Stock. The number of shares of Common Stock to be offered or resold
  by means of the Reoffer Prospectus by the selling stockholders, and any other person with whom any of them is acting in concert for the
  purpose of selling Common Stock, may not exceed, during any three month period, the amount specified in Rule 144(e) under the Securities
  Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As specified in General Instruction C of Form
  S-8, until such time as we meet the registrant requirements for use of Form S-3, the number of shares of Common Stock to be offered by
  means of this reoffer prospectus, by each of the selling securityholders, and any other person with whom he or she is acting in concert
  for the purpose of selling our shares of Common Stock, may not exceed, during any three month period, the amount specified in Rule 144(e)
  of the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 1.</B></FONT></TD>
      <TD STYLE="width: 92%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plan Information.</B></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will provide each recipient of a grant
  under the Plans (the &ldquo;<B>Recipients</B>&rdquo;) with documents that contain information related to the Plans, and other information
  including, but not limited to, the disclosure required by Item 1 of Form S-8, which information is not required to be and is not being
  filed as a part of this Registration Statement on Form S-8 (the &ldquo;<B>Registration Statement</B>&rdquo;) or as prospectuses or prospectus
  supplements pursuant to Rule 424 under the Securities Act. The foregoing information and the documents incorporated by reference in response
  to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a)
  of the Securities Act. A Section 10(a) prospectus will be given to each Recipient who receives shares of Common Stock covered by this
  Registration Statement, in accordance with Rule 428(b)(1) under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 2.</B></FONT></TD>
      <TD STYLE="width: 92%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registrant Information and Employee Plan Annual Information.</B></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will provide to each Recipient a written statement
  advising of the availability of documents incorporated by reference in Item 3 of Part II of this Registration Statement (which documents
  are incorporated by reference in this Section 10(a) prospectus) and of documents required to be delivered pursuant to Rule 428(b) under
  the Securities Act without charge and upon written or oral request by contacting:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Henry C.W. Nisser, Esq.<BR>
  Executive Vice President &amp; General Counsel</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Alzamend Neuro, Inc.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">100 Park Avenue, Suite 1658<BR>
  New York, NY 10017</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>REOFFER PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>25,950,000 Shares</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="alzamendlogo.jpg" ALT=""></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Issuable under certain awards </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>granted under the Plans</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This reoffer prospectus relates
  to the public resale, from time to time, of an aggregate of 25,950,000 shares (the &ldquo;<B>Shares</B>&rdquo;) of our common stock, $0.0001
  par value per share (the &ldquo;<B>Common Stock</B>&rdquo;) by certain securityholders identified herein in the section entitled &ldquo;Selling
  Securityholders&rdquo;. Such shares may be acquired in connection with awards granted under the Alzamend Neuro, Inc. (the &ldquo;<B>Company</B>&rdquo;)
  2016 Amended and Restated Stock Incentive Plan (the &ldquo;<B>2016 Plan</B>&rdquo;), the Company&rsquo;s 2021 Stock Incentive Plan (the
  &ldquo;<B>2021 Plan</B>&rdquo;) and stock options granted to certain employees pursuant to option agreements outside of the Plans (&ldquo;<B>Option
  Agreements</B>&rdquo; and collectively with the 2016 Plan and the 2021 Plan, the &ldquo;<B>Plans</B>&rdquo;). You should read this prospectus
  carefully before you invest in our Common Stock.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Such resales shall take place
  on The Nasdaq Capital Market, or such other stock market or exchange on which our Common Stock may be listed or quoted, in negotiated
  transactions or otherwise, at market prices prevailing at the time of the sale or at prices otherwise negotiated (see &ldquo;Plan of Distribution&rdquo;
  starting on page 9 of this prospectus). We will receive no part of the proceeds from sales made under this reoffer prospectus. The Selling
  Securityholders will bear all sales commissions and similar expenses. Any other expenses incurred by us in connection with the registration
  and offering and not borne by the Selling Securityholders will be borne by us.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This reoffer prospectus has
  been prepared for the purposes of registering our shares of Common Stock under the Securities Act to allow for future sales by Selling
  Securityholders on a continuous or delayed basis to the public without restriction, provided that the amount of shares of Common Stock
  to be offered or resold under this Reoffer Prospectus by each Selling Securityholder or other person with whom he or she is acting in
  concert for the purpose of selling shares of Common Stock, may not exceed, during any three-month period, the amount specified in Rule
  144(e) under the Securities Act. We have not entered into any underwriting arrangements in connection with the sale of the shares covered
  by this reoffer prospectus. The Selling Securityholders identified in this reoffer prospectus, or their pledgees, donees, transferees
  or other successors-in-interest, may offer the shares covered by this reoffer prospectus from time to time through public or private transactions
  at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investing in our Common Stock
  involves risks. See &ldquo;Risk Factors&rdquo; beginning on page&nbsp;3 of this reoffer prospectus. These are speculative securities.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common Stock is quoted
  on The Nasdaq Capital Market under the symbol &ldquo;ALZN&rdquo; and the last reported sale price of our Common Stock on July 12, 2021
  was $6.11 per share.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NEITHER THE SECURITIES
  AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS
  IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is July 13, 2021</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 4 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALZAMEND NEURO, INC.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="vertical-align: top; width: 93%">&nbsp;</TD>
      <TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 5%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary Statement Regarding Forward-Looking Statements</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Securityholders</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation of Certain Documents by Reference</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure of Commission Position on Indemnification For Securities Act Liabilities</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You can Find Additional Information </FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 5 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Except where the context
  otherwise requires, the terms, &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo; or &ldquo;the Company,&rdquo; refer to the business
  of Alzamend Neuro, Inc., a Delaware corporation. </I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>CAUTIONARY STATEMENT
  REGARDING FORWARD-LOOKING STATEMENTS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus, including
  the documents that we incorporate by reference, contains forward-looking statements. All statements other than statements of historical
  fact are, or may be deemed to be, forward-looking statements. Such forward-looking statements include statements regarding, among others,
  (a)&nbsp;our expectations about possible business combinations, (b)&nbsp;our growth strategies, (c)&nbsp;our future financing plans, and
  (d)&nbsp;our anticipated needs for working capital. Forward-looking statements, which involve assumptions and describe our future plans,
  strategies, and expectations, are generally identifiable by use of the words &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo;
  &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;approximate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;believe,&rdquo; &ldquo;intend,&rdquo;
  &ldquo;plan,&rdquo; &ldquo;budget,&rdquo; &ldquo;could,&rdquo; &ldquo;forecast,&rdquo; &ldquo;might,&rdquo; &ldquo;predict,&rdquo; &ldquo;shall&rdquo;
  or &ldquo;project,&rdquo; or the negative of these words or other variations on these words or comparable terminology. This information
  may involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements
  to be materially different from the future results, performance, or achievements expressed or implied by any forward-looking statements.
  These statements may be found in this prospectus, including the documents that we incorporate by reference.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Forward-looking statements
  are based on our current expectations and assumptions regarding our business, potential target businesses, the economy and other future
  conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks,
  and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking
  statements as a result of various factors, including, without limitation, changes in local, regional, national or global political, economic,
  business, competitive, market (supply and demand) and regulatory conditions and the following:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 6%">&nbsp;</TD>
      <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to effectively execute our business strategy;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to manage our expansion, growth and operating expenses;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to evaluate and measure our business, prospects and performance metrics;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to compete and succeed in a highly competitive and evolving industry;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to respond and adapt to changes in technology and customer behavior; </FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to protect our intellectual property and to develop, maintain and enhance a strong brand; </FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our significant losses since inception and anticipation that we will continue to incur significant losses for the foreseeable future;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our need for substantial additional funding to finance our operations and complete development to seek U.S. Food and Drug Administration (&ldquo;<B>FDA</B>&rdquo;) approval for AL001 and AL002 before commercialization;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reliance on licenses from a third party regarding our rights and development of AL001 and AL002;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our development of AL001 and AL002 never leading to a marketable product;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our product candidates not qualifying for expedited development, or if they do, not actually leading to a faster development or regulatory review or approval process; and</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our approach to targeting beta-amyloid plaque via AL002 being based on a novel therapeutic approach.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We caution you therefore that
  you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future
  performance.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information regarding market
  and industry statistics contained in this prospectus, including the documents that we incorporate by reference, is included based on information
  available to us that we believe is accurate. It is generally based on academic and other publications that are not produced for purposes
  of securities offerings or economic analysis. Forecasts and other forward-looking information obtained from these sources are subject
  to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance
  of products and services. Except as required by U.S. federal securities laws, we have no obligation to update forward-looking information
  to reflect actual results or changes in assumptions or other factors that could affect those statements.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;&nbsp;</P>
  
  <DIV STYLE="padding-right: 2%; padding-left: 2%; border: Black 1pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUMMARY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The Commission allows us to &lsquo;&lsquo;incorporate
  by reference&rsquo;&rsquo; certain information that we file with the Commission, which means that we can disclose important information
  to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus, and
  information that we file later with the Commission will update automatically, supplement and/or supersede the information disclosed in
  this prospectus. Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus shall
  be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or
  in any other document that also is or is deemed to be incorporated by reference in this prospectus modifies or supersedes such statement.
  Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
  You should read the following summary together with the more detailed information regarding our company, our Common Stock and our financial
  statements and notes to those statements appearing elsewhere in this prospectus or incorporated herein by reference.</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Our Company</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a preclinical stage
  biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders.
  With our two current and future product candidates, we aim to bring treatments or cures to market at a reasonable cost as quickly as possible.
  Far too many individuals&thinsp;&mdash;&thinsp;patients and caregivers&thinsp;&mdash;&thinsp;suffer from the burden created by these devastating,
  and often fatal, diseases. Our primary target, Alzheimer&rsquo;s Disease, was among the most-feared diseases (second only to cancer) among
  Americans, according to a 2011 survey by the Harvard School of Public Health. Alzheimer&rsquo;s is also the sixth leading cause of death
  in the United States according to a 2021 report from the Alzheimer&rsquo;s Association, a nonprofit that funds research. Existing Alzheimer&rsquo;s
  treatments only temporarily relieve symptoms but do not slow or halt the underlying worsening of the disease, which currently affects
  roughly 6.2&nbsp;million Americans and that number is expected to grow to 13&nbsp;million individuals by 2050. Alzheimer&rsquo;s also
  impacts more than 11&nbsp;million Americans who provide an estimated 15.3&nbsp;billion hours of unpaid care per year, valued at $257&nbsp;billion,
  according to data provided by the Alzheimer&rsquo;s Association. In 2021, the estimated healthcare costs for treating individuals with
  Alzheimer&rsquo;s in the United States will be $355&nbsp;billion, including $239&nbsp;billion in Medicare and Medicaid payments. These
  costs could rise to as high as $1.1 trillion per year by 2050 if no permanent treatment or cure for Alzheimer&rsquo;s is found, the Alzheimer&rsquo;s
  Association reported.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Corporate Information</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated on February&nbsp;26,
  2016 as Alzamend Neuro, Inc. under the laws of the State of Delaware. Our executive offices are located at 3802 Spectrum Blvd., Suite
  112C, Tampa, Florida 33612 and our telephone number is (844) 722-6333. We maintain a corporate website at www.alzamend.com. The information
  on our website is not part of this prospectus. We have included our website address as a factual reference and do not intend it to be
  active link to our website.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>
  
  <!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  <DIV STYLE="padding-right: 2%; padding-left: 2%; border: Black 1pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Offering</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding Common Stock:</B></FONT></TD>
      <TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 73%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85,304,525 shares of our Common Stock are outstanding as of July 12, 2021.</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common Stock Offered:</B></FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 25,950,000 shares of Common Stock for sale by the selling securityholders (which include our executive officers and directors) for their own account pursuant to the Plans.</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selling Securityholders:</B></FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The selling securityholders are set forth in the section entitled &ldquo;Selling Securityholders&rdquo; of this reoffer prospectus on page 6.&nbsp;&nbsp;The amount of securities to be offered or resold by means of the reoffer prospectus by the designated selling securityholders may not exceed, during any three month period, the amount specified in Rule 144(e).</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds:</B></FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will not receive any proceeds from the sale of our Common Stock by the selling securityholders. We would, however, receive proceeds upon the exercise of the stock options by those who receive options under the Plans and exercise such options for cash. Any cash proceeds will be used by us for general corporate purposes.</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk Factors:</B></FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The securities offered hereby involve a high degree of risk. See &ldquo;Risk Factors.&rdquo;</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq Capital Market trading <BR>
  symbol:</B></FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ALZN</P></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>
  
  <!-- Field: Page; Sequence: 8 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISK FACTORS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An investment in shares of our Common Stock is
  highly speculative and involves a high degree of risk. We face a variety of risks that may affect our operations or financial results
  and many of those risks are driven by factors that we cannot control or predict. Before investing in our Common Stock, you should carefully
  consider the risks below and set forth under the caption &ldquo;Risk Factors&rdquo; in our Registration Statement on Form S-1, as amended
  (File No. 333-255955), filed with the Securities and Exchange Commission on June 11, 2021, which are incorporated by reference herein,
  and subsequent reports filed with the SEC, together with the financial and other information contained or incorporated by reference in
  this prospectus. If any of these risks actually occurs, our business, prospects, financial condition and results of operations could be
  materially adversely affected. In that case, the trading price of our Common Stock would likely decline and you may lose all or a part
  of your investment. Only those investors who can bear the risk of loss of their entire investment should invest in our Common Stock.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Relating to Ownership of Our Common Stock</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our stock price may be volatile, and the
  value of our Common Stock may decline.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of our Common
  Stock may be highly volatile and may fluctuate or decline substantially as a result of a variety of factors, some of which are beyond
  our control, including:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>announcements of the failure to obtain regulatory approvals or receipt of a &ldquo;complete response letter&rdquo; from the FDA;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>announcements of restricted label indications or patient populations, or changes or delays in regulatory review processes;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>announcements of therapeutic innovations or new products by us or our competitors;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing
  activities;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>changes or developments in laws or regulations applicable to our product candidates;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>the failure of our testing and clinical trials;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -0.35pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>the impact of the ongoing COVID-19 pandemic on our business;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>product liability claims, other litigation or public concern about the safety of our product candidates or future products;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -0.35pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>any adverse changes to our relationship with licensors, manufacturers or suppliers;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>the loss of any of our key scientific or management personnel;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>any major changes in our Board of Directors or management;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>the failure to obtain new commercial partners;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>announcements concerning our competitors or the pharmaceutical industry in general;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>the failure to achieve expected product sales and profitability;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>the failure to obtain reimbursements for our product candidates as part of any healthcare insurance plan, or reductions in such reimbursements;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>actual or anticipated fluctuations in our cash position or operating results;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>manufacturing, supply or distribution shortages related to our current or future product candidates for our development programs and
  commercialization;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>changes in financial estimates or recommendations by securities analysts;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>
  
  <!-- Field: Page; Sequence: 9 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>the termination of any of our existing license agreements;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>announcements relating to future licensing or development agreements;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>potential acquisitions;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>the trading volume of shares on The Nasdaq Capital Market;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>sales of our shares by us, our executive officers or directors or our shareholders;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>fluctuations in the U.S. equity markets;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>changes in accounting principles;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>market conditions in the healthcare sector; and</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 26.65pt">&bull;</TD><TD>general economic conditions in the United States and elsewhere.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: yellow"></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In recent&nbsp;years, each
  of the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant
  price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies
  whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price
  of our Common Stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market
  for our Common Stock shortly following this offering. Following periods of such volatility in the market price of a company&rsquo;s securities,
  securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price,
  we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&rsquo;s
  attention and resources from our business.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A significant portion of our total outstanding
  shares is restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our
  Common Stock to decline significantly, even if our business is doing well.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of a substantial number
  of shares of our Common Stock in the public market could occur at any time. These sales, upon the expiration of any or all of the lock-up
  agreements entered into between the representative and each of our directors, executive officers and substantially all holders of more
  than 5% of our outstanding Common Stock, as well as certain other parties (the &ldquo;lock-up agreements&rdquo;), the early release from
  these agreements or the perception in the market that the holders of a large number of shares of our Common Stock intend to sell shares,
  could cause the market price of our Common Stock to fall and could impair our ability to raise capital by selling additional securities.
  As of July 12, 2021, we have 85,304,525 shares of Common Stock outstanding. Of these shares, 2,875,000 shares that were sold in our initial
  public offering are freely tradable without restriction or further registration under the Securities Act, except for any shares purchased
  by holders subject to lock-up agreements or by any of our affiliates within the meaning of Rule 144 under the Securities Act, which generally
  includes executive officers, directors and 10% stockholders. Of the 85,304,525 shares of our Common Stock outstanding, a significant amount
  of them are locked-up as a result of the lock-up agreements that existing stockholders have signed restricting their ability to transfer
  our stock for 180 days after June 14, 2021. Certain of these holders will be subject to a lock-up agreement that will allow them to sell,
  beginning 90 days after June 14, 2021 (the &ldquo;Leak-Out Period Commencement Date&rdquo;), up to 33.3% of their shares and any other
  Locked-Up Securities (as defined herein) in any rolling 30-day period, with a daily cap of 10% of the traded volume on Nasdaq. Holders
  subject to this version of the lock-up agreement will be released from such lock-up upon the earlier of (i)&nbsp;the 90th day after the
  Leak-Out Period Commencement Date and (ii)&nbsp;the meeting of certain stock price and trading volume thresholds, which release would
  be no earlier than the 10th trading day after the Leak-Out Period Commencement Date. Substantially all of the remaining shares, held by
  persons who are not deemed to be affiliates (at the time of or at any time during the three months preceding a sale), were either sold
  by us in a Regulation A offering and are freely transferable or are restricted securities under Rule 144, in that they were issued in
  private transactions not involving a public offering, and have been beneficially owned for at least one year. All of these remaining shares
  are currently eligible for sale. In addition, the potential future exercise of warrants and stock options to purchase our Common Stock
  and conversion of convertible debt instruments into our Common Stock could result in our issuing a significant number of additional shares
  of Common Stock. Pursuant to this prospectus, we are registering all shares of Common Stock that we may issue under our stock incentive
  plans, which can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates
  and the lock-up agreements described above. If any of these additional shares are sold, or if it is perceived that they will be sold,
  in the public market, the market price of our Common Stock could decline significantly, even if our business is doing well.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>
  
  <!-- Field: Page; Sequence: 10 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may fail to meet our publicly announced
  guidance or other expectations about our business, which would cause our stock price to decline.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to provide guidance
  regarding our expected financial and business performance, such as projections regarding sales and product development, as well as anticipated
  future revenues, gross margins, profitability and cash flows. Correctly identifying key factors affecting business conditions and predicting
  future events is inherently an uncertain process and our guidance may not be accurate. Our guidance is based on certain assumptions such
  as those relating to anticipated FDA approval for our product candidates, the results of our clinical trials, the marketing of any of
  our product candidates, among many other factors. If our guidance is not accurate or varies from actual results due to our inability to
  meet our assumptions or the impact on our financial performance that could occur as a result of various risks and uncertainties, the market
  value of our Common Stock could decline significantly.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our issuance of additional capital stock
  in connection with financings, acquisitions, investments, our equity incentive plans or otherwise will dilute all other stockholders.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">We
  expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect to grant equity
  awards to employees, directors and consultants under our equity incentive plans. We may also raise capital through equity financings in
  the future. As part of our business strategy, we may acquire or make investments in companies, products or technologies and issue equity
  securities to pay for any such acquisition or investment. Any such issuances of additional capital stock may cause stockholders to experience
  significant dilution of their ownership interests and the per share value of our Common Stock to decline.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because we do not intend to pay dividends
  on our Common Stock, you must rely on stock appreciation for any return on your investment.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We presently intend to retain
  any future earnings and do not expect to pay any dividends in the foreseeable future. As a result, you must rely on stock appreciation
  and a liquid trading market for any return on your investment. If an active and liquid trading market does not develop, you may be unable
  to sell your shares of Common Stock at a price above which you paid for your shares.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If securities analysts do not publish research
  or reports about our business or if they publish negative evaluations of our stock, the price of our Common Stock could decline.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
  Common Stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. We do
  not currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of
  us, the trading price of our Common Stock could decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering
  our business downgrade their evaluations of our stock, the price of our Common Stock could decline. If one or more of these analysts cease
  to cover our stock, we could lose visibility in the market for our Common Stock, which in turn could cause our stock price to decline.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>USE OF PROCEEDS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares which may be sold
  under this reoffer prospectus will be sold for the respective accounts of each of the Selling Securityholders listed herein (which includes
  our executive officers and directors). Accordingly, we will not realize any proceeds from the sale of the shares of our Common Stock.
  We will receive proceeds from the exercise of the options; however, no assurance can be given as to when or if any or all of the options
  will be exercised. If any options are exercised, the proceeds derived therefrom will be used for working capital and general corporate
  purposes. All expenses of the registration of the shares will be paid by us. See &ldquo;Selling Securityholders&rdquo; and &ldquo;Plan
  of Distribution.&rdquo;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 11 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SELLING SECURITYHOLDERS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are registering for resale
  the shares covered by this prospectus to permit the Selling Securityholders identified below and their pledgees, donees, transferees and
  other successors-in-interest that receive their securities from a Selling Securityholder as a gift, partnership distribution or other
  non-sale related transfer after the date of this prospectus to resell the shares when and as they deem appropriate. The Selling Securityholders
  acquired, or may acquire, these shares from us pursuant to the Plans. The shares may not be sold or otherwise transferred by the Selling
  Securityholders unless and until the applicable awards vest and are exercised, as applicable, in accordance with the terms and conditions
  of the Plans.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The following table sets forth:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the name of each Selling Securityholder;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the position(s), office or other material relationship with our company and its predecessors or affiliates, over the last three years of each Selling Securityholder;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number and percentage of shares of our Common Stock that each Selling Securityholder beneficially owned as of July 12, 2021 prior to the offering for resale of the shares under this prospectus;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of shares of our Common Stock that may be offered for resale for the account of each Selling Securityholder under this prospectus; and</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number and percentage of shares of our Common Stock to be beneficially owned by each Selling Securityholder after the offering of the resale shares (assuming all of the offered resale shares are sold by such Selling Securityholder).</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information with respect to
  beneficial ownership is based upon information obtained from the Selling Securityholders.&nbsp;&nbsp;Because the Selling Securityholders
  may offer all or part of the shares of Common Stock, which they own pursuant to the offering contemplated by this reoffer prospectus,
  and because its offering is not being underwritten on a firm commitment basis, no estimate can be given as to the amount of shares that
  will be held upon termination of this offering.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares in the
  column &lsquo;&lsquo;Number of Shares Being Offered&rsquo;&rsquo; represents all of the shares of our Common Stock that each Selling Securityholder
  may offer under this prospectus. We do not know how long the Selling Securityholders will hold the shares before selling them or how many
  shares they will sell. The shares of our Common Stock offered by this prospectus may be offered from time to time by the Selling Securityholders
  listed below. We cannot assure you that any of the Selling Securityholders will offer for sale or sell any or all of the shares of Common
  Stock offered by them by this prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Number of Shares Beneficially</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Owned Prior to Offering (1)</B></P>
  
  </TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
      <TD COLSPAN="2" STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;Number
                                              of</B></P>
  
  <P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><B>Shares Being</B></P></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
      <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Number
                                              of Shares Beneficially</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Owned After Offering
  (2)</B></P>
  
  </TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: left"><B>Securityholders</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><B>Number</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><B>Percent<BR> (%)</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><B>Offered</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><B>Number</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><B>Percent (%)</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; width: 40%; text-align: left">Milton C. Ault, III (3)</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">39,156,055</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">41.59</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,500,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">36,656,055</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">38.93</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="white-space: nowrap; text-align: left">Stephan Jackman (4)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,062,500</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.36</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; text-align: left">William B. Horne (5)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,645,833</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.01</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="white-space: nowrap; text-align: left">Henry C.W. Nisser (6)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">729,167</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,250,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; text-align: left">Lien T. Escalona (7)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,500</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="white-space: nowrap; text-align: left">Kenneth S. Cragun (8)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.16</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; text-align: left">David Katzoff (9)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">784,292</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="white-space: nowrap; text-align: left">Mark Gustafson (10)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; text-align: left">Lynne Fahey McGrath (11)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="white-space: nowrap; text-align: left">Jeffrey Oram (12)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; text-align: left">Andrew H. Woo (13)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="white-space: nowrap; text-align: left">Phil Mansour (14)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.85</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; text-align: left">Garry Gottlieb (15)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,375,133</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.60</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">729,300</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="white-space: nowrap; text-align: left">Chuanhai Cao (16)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,079,148</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.42</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,620,815</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.89</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; text-align: left">Named Selling Stockholders (17)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">390,064</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,300,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,001</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
    </TABLE>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*less than 1%</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">The number and percentage of shares beneficially owned is determined in accordance with Rule&nbsp;13d-3
  of the Securities Exchange Act of 1934, as amended, and the information is not necessarily indicative of beneficial ownership for any
  other purpose. Under such rule, beneficial ownership includes any shares as to which the Selling Securityholder has sole or shared voting
  power or investment power and also any shares which the Selling Securityholder has the right to acquire within 60 days. Applicable percentage
  ownership is based on 85,304,525 shares of Common Stock outstanding as of July 12, 2021.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 12 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Assumes that all shares of Common Stock to be offered, as set forth above, are sold pursuant to this offering
  and that no other shares of Common Stock are acquired or disposed of by the Selling Securityholders prior to the termination of this offering.
  Because the Selling Securityholders may sell all, some or none of their shares of Common Stock or may acquire or dispose of other shares
  of Common Stock, no reliable estimate can be made of the aggregate number of shares of Common Stock that will be sold pursuant to this
  offering or the number or percentage of shares of Common Stock that each Selling Securityholder will own upon completion of this offering.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Mr. Ault is our Founder and Chairman Emeritus. He served as our Executive Chairman from November 2018
  until our initial public offering in June 2021. The shares of Common Stock beneficially owned prior to this offering include 2,500,000
  shares of Common Stock issuable upon exercise of options which are currently exercisable, 15,000,000 shares of Common Stock owned by owned
  by Ault Life Sciences, Inc. (&ldquo;<B>Ault Life Sciences</B>&rdquo;), 10,000,000 shares of Common Stock and 5,000,000 shares of Common
  Stock underlying warrants owned by Ault Life Sciences Fund, LLC (&ldquo;<B>Ault Fund</B>&rdquo;), and 5,306,055 shares of Common Stock
  and 1,350,000 shares of Common Stock underlying warrants owned by Digital Power Lending, LLC (&ldquo;<B>DP Lending</B>&rdquo;). Mr. Ault
  has sole voting and investment power with respect to the securities held of record by Ault Life Sciences and Ault Fund. DP Lending is
  a wholly-owned subsidiary of Ault Global Holdings, Inc. (&ldquo;<B>AGH</B>&rdquo;). Mr. Ault, the Executive Chairman of AGH, is deemed
  to have voting and investment power with respect to the securities held of record by DP Lending. The shares of Common Stock registered
  for resale hereunder represent shares issuable upon exercise of vested stock options.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">Mr. Jackman is our Chief Executive Officer and a member of the Board. The shares of Common Stock beneficially
  owned prior to this offering represent shares of Common Stock issuable upon exercise of options which are currently exercisable or become
  exercisable within 60 days. The shares of Common Stock registered for resale hereunder represent shares issuable upon exercise of vested
  and unvested stock options.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(5)</TD><TD STYLE="text-align: justify">Mr. Horne is our Chairman of the Board. The shares of Common Stock beneficially owned prior to this offering
  represent shares of Common Stock issuable upon exercise of options which are currently exercisable or become exercisable within 60 days.
  The shares of Common Stock registered for resale hereunder represent shares issuable upon exercise of vested and unvested stock options.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(6)</TD><TD STYLE="text-align: justify">Mr. Nisser is our Executive Vice President, General Counsel and a member of the Board. The shares of Common
  Stock beneficially owned prior to this offering represent shares of Common Stock issuable upon exercise of options which are currently
  exercisable or become exercisable within 60 days. The shares of Common Stock registered for resale hereunder represent shares issuable
  upon exercise of vested and unvested stock options.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(7)</TD><TD STYLE="text-align: justify">Ms. Escalona is our Chief Financial Officer. The shares of Common Stock registered for resale hereunder
  represent shares issuable upon exercise of unvested stock options.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(8)</TD><TD STYLE="text-align: justify">Mr. Cragun is our Senior Vice President of Finance. The shares of Common Stock beneficially owned prior
  to this offering represent shares of Common Stock issuable upon exercise of options which are currently exercisable or become exercisable
  within 60 days. The shares of Common Stock registered for resale hereunder represent shares issuable upon exercise of vested and unvested
  stock options.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(9)</TD><TD STYLE="text-align: justify">Mr. Katzoff is our Chief Operating Officer. The shares of Common Stock beneficially owned prior to this
  offering include 757,292 shares of Common Stock issuable upon exercise of options which are currently exercisable or become exercisable
  within 60 days and 9,000 shares of Common Stock underlying warrants. The shares of Common Stock registered for resale hereunder represent
  shares issuable upon exercise of vested and unvested stock options.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(10)</TD><TD STYLE="text-align: justify">Mr. Gustafson is a member of the Board. The shares of Common Stock registered for resale hereunder represent
  shares issuable upon exercise of unvested stock options and shares of Common Stock issuable upon settlement of unvested restricted stock
  grants.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(11)</TD><TD STYLE="text-align: justify">Dr. McGrath is a member of the Board. The shares of Common Stock registered for resale hereunder represent
  shares issuable upon exercise of unvested stock options and shares of Common Stock issuable upon settlement of unvested restricted stock
  grants.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(12)</TD><TD STYLE="text-align: justify">Mr. Oram is a member of the Board. The shares of Common Stock registered for resale hereunder represent
  shares issuable upon exercise of unvested stock options and shares of Common Stock issuable upon settlement of unvested restricted stock
  grants.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(13)</TD><TD STYLE="text-align: justify">Dr. Woo is a member of the Board. The shares of Common Stock registered for resale hereunder represent
  shares issuable upon exercise of unvested stock options and shares of Common Stock issuable upon settlement of unvested restricted stock
  grants.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 13 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(14)</TD><TD STYLE="text-align: justify">Mr. Mansour was a member of the Board until our initial public offering in June 2021. The shares of Common
  Stock beneficially owned prior to this offering represent shares of Common Stock issuable upon exercise of options which are currently
  exercisable. The shares of Common Stock registered for resale hereunder represent shares issuable upon exercise of vested stock options.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(15)</TD><TD STYLE="text-align: justify">Gary Gottlieb is a former employee of Alzamend. The shares of Common Stock beneficially owned prior to
  this offering include 645,833 shares of Common Stock issuable upon exercise of options which are currently exercisable or become exercisable
  within 60 days and 187,500 shares owned by Buckeye Quad Trust. Mr. Gottlieb, as the Trustee of Buckeye Quad Trust, has investment and
  voting control over the shares held by this entity. The shares of Common Stock registered for resale hereunder represent shares issuable
  upon exercise of vested and unvested stock options.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(16)</TD><TD STYLE="text-align: justify">Chuanhai Cao is a consultant to Alzamend. The shares of Common Stock beneficially owned prior to this
  offering include 458,333 shares of Common Stock issuable upon exercise of options which are currently exercisable or become exercisable
  within 60 days. The shares of Common Stock registered for resale hereunder represent shares issuable upon exercise of vested and unvested
  stock options.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 31.5pt">(17)</TD><TD STYLE="text-align: justify">Includes the following 16 named&nbsp;non-affiliate&nbsp;persons, each of whom beneficially owns at least
  1,000 Shares: Sonsorey Corbin; Eve del Rio; Therese Doherty; Laura Kim; Eric McDade; Donald Reitberg; Michael Rooney; Kenny Seaver; Arthur
  Spalding; Georgia Thompson; James M. Turner; Kirk Van Ness; Janan Van Osdell; Brianna Wharton; Thomas Wisniewski; and Gary Wolfe. <FONT STYLE="background-color: white">Each
  of these persons beneficially owns less than 1% of our Common Stock.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 14 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLAN OF DISTRIBUTION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
  are registering the Shares covered by this prospectus to permit the Selling Stockholders to conduct public secondary trading of these
  Shares from time to time after the date of this prospectus. We will not receive any of the proceeds of the sale of the Shares offered
  by this prospectus. The aggregate proceeds to the Selling Stockholders from the sale of the Shares will be the purchase price of the Shares
  less any discounts and commissions. We will not pay any brokers&rsquo; or underwriters&rsquo; discounts and commissions in connection
  with the registration and sale of the Shares covered by this prospectus. The Selling Stockholders reserve the right to accept and, together
  with their respective agents, to reject, any proposed purchases of Shares to be made directly or through agents.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The Shares offered by
  this prospectus may be sold from time to time to purchasers:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 5%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">directly by the Selling Stockholders, or</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 5%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, commissions or agent&rsquo;s commissions from the Selling Stockholders or the purchasers of the Shares.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
  underwriters, broker-dealers or agents who participate in the sale or distribution of the Shares may be deemed to be &ldquo;underwriters&rdquo;
  within the meaning of the Securities Act. As a result, any discounts, commissions or concessions received by any such broker-dealer or
  agents who are deemed to be underwriters will be deemed to be underwriting discounts and commissions under the Securities Act. Underwriters
  are subject to the prospectus delivery requirements of the Securities Act and may be subject to certain statutory liabilities under the
  Securities Act and the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). We will make copies of this prospectus
  available to the Selling Stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. To our
  knowledge, there are currently no plans, arrangements or understandings between the Selling Stockholders and any underwriter, broker-dealer
  or agent regarding the sale of the Shares by the Selling Stockholders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The Shares may be sold
  in one or more transactions at:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 5%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">fixed prices;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 5%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">prevailing market prices at the time of sale;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 5%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">prices related to such prevailing market prices;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 5%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">varying prices determined at the time of sale; or</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 5%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">negotiated prices.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">These sales may be effected
  in one or more transactions:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 5%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">on any national securities exchange or quotation service on which the Shares may be listed or quoted at the time of sale, including the NYSE;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 5%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">in the&nbsp;over-the-counter&nbsp;market;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 5%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">in transactions otherwise than on such exchanges or services or in the&nbsp;over-the-counter&nbsp;market;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 5%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">any other method permitted by applicable law; or</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 5%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">through any combination of the foregoing.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These
  transactions may include block transactions or crosses. Crosses are transactions in which the same broker acts as an agent on both sides
  of the trade.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">At
  the time a particular offering of the Shares is made, a prospectus supplement, if required, will be distributed, which will set forth
  the name of the Selling Stockholders, the aggregate amount of Shares being offered and the terms of the offering, including, to the extent
  required, (1)&nbsp;the name or names of any underwriters, broker-dealers or agents, (2)&nbsp;any discounts, commissions and other terms
  constituting compensation from the Selling Stockholders and (3)&nbsp;any discounts, commissions or concessions allowed or reallowed to
  be paid to broker-dealers.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
  Selling Stockholders will act independently of us in making decisions with respect to the timing, manner, and size of each resale or other
  transfer. There can be no assurance that the Selling Stockholders will sell any or all of the Shares under this prospectus. Further, we
  cannot assure you that the Selling Stockholders will not transfer, distribute, devise or gift the Shares by other means not described
  in this prospectus. In addition, any Shares covered by this prospectus that qualify for sale under Rule 144 of the Securities Act may
  be sold under Rule 144 rather than under this prospectus. The Shares may be sold in some states only through registered or licensed brokers
  or dealers. In addition, in some states the Shares may not be sold unless they have been registered or qualified for sale or an exemption
  from registration or qualification is available and complied with.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 15 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
  Selling Stockholders and any other person participating in the sale of the Shares will be subject to the Exchange Act. The Exchange Act
  rules include, without limitation, Regulation M, which may limit the timing of purchases and sales of any of the Shares by the Selling
  Stockholders and any other person. In addition, Regulation M may restrict the ability of any person engaged in the distribution of the
  Shares to engage in market-making activities with respect to the particular Shares being distributed. This may affect the marketability
  of the Shares and the ability of any person or entity to engage in market-making activities with respect to the Shares.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
  Selling Stockholders may indemnify any broker or underwriter that participates in transactions involving the sale of the Shares against
  certain liabilities, including liabilities arising under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEGAL MATTERS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the issuance
  of the securities offered by this prospectus will be passed upon for us by&nbsp;Olshan Frome Wolosky LLP, New York, New York.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPERTS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements of
  Alzamend Neuro, Inc. as of April 30, 2020 and 2019 and for each of the two years in the period ended April 30, 2020 incorporated by reference
  in this Prospectus and Registration Statement from the Company&rsquo;s Registration Statement on form S-1 (No. 333-255955), as amended,
  have been audited by Squar Milner LLP (which effective as of November 1, 2020, merged with Baker Tilly US, LLP), an independent registered
  public accounting firm, as stated in their report thereon (which report expresses an unqualified opinion and includes an explanatory paragraph
  relating to the Company&rsquo;s ability to continue as a going concern), incorporated herein by reference, and have been incorporated
  in this Prospectus and Registration Statement in reliance upon such report and upon the authority of such firm as experts in accounting
  and auditing.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following documents filed
  with the SEC are hereby incorporated by reference in this prospectus (unless otherwise noted, the SEC file number for each of the documents
  listed below is 001-40483):</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 57px">&nbsp;</TD>
      <TD STYLE="width: 45px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 4 to the Registrant&rsquo;s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on June 11, 2021 (File No. 333-255955), which contains the Registrant&rsquo;s audited financial statements for the latest fiscal year for which such statements have been filed</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in">&nbsp;&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 57px">&nbsp;</TD>
      <TD STYLE="width: 45px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&rsquo;s Prospectus filed on June 15, 2021 pursuant to Rule 424(b) under the Securities Act, relating to the Registration Statement on Form S-1, as amended (File No. 333-255955).</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-align: justify; text-indent: -34pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 57px">&nbsp;</TD>
      <TD STYLE="width: 45px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Report on Form&nbsp;8-K filed on June 22, 2021; and</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-indent: -34pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 57px">&nbsp;</TD>
      <TD STYLE="width: 45px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of the Registrant&rsquo;s Common Stock which is contained in a registration statement on Form 8-A filed on June 11, 2021 under the Exchange Act, including any amendment or report filed for the purpose of updating such description.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-indent: -0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">All documents filed by the
  Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and
  prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been
  sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement
  and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been
  furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Any statement contained in
  a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of
  this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed
  to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be
  deemed, except as so modified or superseded, to constitute a part of this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR SECURITIES ACT LIABILITIES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
  for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the registrant, the registrant
  has been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act
  and is therefore unenforceable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 16 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WHERE&nbsp;YOU CAN FIND MORE INFORMATION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We file annual, quarterly
  and other reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet
  at the SEC&rsquo;s website at http://www.sec.gov. Our Annual Report on Form&nbsp;10-K,&nbsp;Quarterly Reports on Form&nbsp;10-Q&nbsp;and
  Current Reports on Form&nbsp;8-K,&nbsp;including any amendments to those reports, and other information that we file with or furnish to
  the SEC pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act can also be accessed free of charge by linking directly from our website
  at www.alzamend.com. These filings will be available as soon as reasonably practicable after we electronically file such material with,
  or furnish it to, the SEC. Information contained on our website is not part of this prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Registrant hereby undertakes
  to provide without charge to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, upon written
  or oral request of any such person, a copy of any and all of the information that has been incorporated by reference in this prospectus
  but not delivered with the prospectus other than the exhibits to those documents, unless the exhibits are specifically incorporated by
  reference into the information that this prospectus incorporates. Requests for documents should be directed to Alzamend Neuro, Inc., Attention:
  Investor Relations, 3802 Spectrum Boulevard, Suite 112C, Tampa, Florida 33612, (844) 722-6333.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>
  
  <!-- Field: Page; Sequence: 17 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALZAMEND NEURO, INC.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="alzamendlogo.jpg" ALT="">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 10%"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">25,950,000 SHARES OF COMMON STOCK</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 10%"><DIV STYLE="border-top: Black 2px solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">REOFFER PROSPECTUS</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 10%"><DIV STYLE="border-top: Black 2px solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">July 13, 2021</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>
  
  <!-- Field: Page; Sequence: 18 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 3. Incorporation of Documents by Reference.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following documents filed
  with the SEC are hereby incorporated by reference in this prospectus (unless otherwise noted, the SEC file number for each of the documents
  listed below is 001-40483):</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 57px">&nbsp;</TD>
      <TD STYLE="width: 45px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 4 to the Registrant&rsquo;s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on June 11, 2021 (File No. 333-255955), which contains the Registrant&rsquo;s audited financial statements for the latest fiscal year for which such statements have been filed</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in">&nbsp;&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 57px">&nbsp;</TD>
      <TD STYLE="width: 45px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&rsquo;s Prospectus filed on June 15, 2021 pursuant to Rule 424(b) under the Securities Act, relating to the Registration Statement on Form S-1, as amended (File No. 333-255955).</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-align: justify; text-indent: -34pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 57px">&nbsp;</TD>
      <TD STYLE="width: 45px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Report on Form&nbsp;8-K filed on June 22, 2021; and</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-indent: -34pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 57px">&nbsp;</TD>
      <TD STYLE="width: 45px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of the Registrant&rsquo;s Common Stock which is contained in a registration statement on Form 8-A filed on June 11, 2021 under the Exchange Act, including any amendment or report filed for the purpose of updating such description.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-indent: -0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All documents filed by the
  Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and
  prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been
  sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement
  and to be part hereof from the date of filing of such documents;&nbsp;<I>provided</I>,&nbsp;<I>however</I>, that documents or information
  deemed to have been furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into
  this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall
  be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or
  in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.
  Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration
  Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 4. Description of Securities.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 5. Interests of Named Experts and Counsel.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 6. Indemnification of Directors and Officers.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As permitted by Delaware law,
  our certificate of incorporation provides that no director will be liable to us or our stockholders for monetary damages for breach of
  certain fiduciary duties as a director. The effect of this provision is to restrict our rights and the rights of our stockholders in derivative
  suits to recover monetary damages against a director for breach of certain fiduciary duties as a director, except that a director will
  be personally liable for:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">any breach of his or her duty of loyalty to us or our stockholders;</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">acts or omissions not in good faith which involve intentional misconduct or a knowing violation of law;</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">the payment of dividends or the redemption or purchase of stock in violation of Delaware law; or</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">any transaction from which the director derived an improper personal benefit.</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This provision does not affect
  a director&rsquo;s liability under the federal securities laws.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At present, we do not maintain
  directors&rsquo; and officers&rsquo; liability insurance in order to limit the exposure to liability for indemnification of directors
  and officers, including liabilities under the Securities Act; however, we are in the process of obtaining such insurance.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 19 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
  for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant
  pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange
  Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event
  that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a
  director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by
  such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion
  of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
  such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication
  of such issue.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7. Exemption from Registration Claimed.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The issuance of the Shares
  being offered by the Form S-3 resale prospectus were deemed to be exempt from registration under the Securities Act in reliance upon Section
  4(a)(2) of the Securities Act (or Regulation D or Regulation S promulgated thereunder), or Rule 701 promulgated under Section 3(b) of
  the Securities Act as transactions by an issuer not involving any public offering or pursuant to benefit plans and contracts relating
  to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions
  to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate
  legends were placed upon the stock certificates issued in these transactions. All recipients had adequate access, through their relationships
  with us, to information about the Registrant.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 8. Exhibits.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD COLSPAN="13" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incorporated by Reference</B></FONT></TD>
      </TR>
    <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD COLSPAN="13" STYLE="text-align: center">&nbsp;</TD>
      </TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="white-space: nowrap">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number</B></P></TD>
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD>
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form</B></P>
  
  </TD>
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="white-space: nowrap">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>File</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number</B></P></TD>
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD STYLE="white-space: nowrap">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="white-space: nowrap">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Filing</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date</B></P></TD>
      </TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD>
      <TD COLSPAN="4">&nbsp;</TD>
      <TD COLSPAN="4">&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1677077/000161577416006901/filename3.htm">Certificate of Incorporation of the Registrant, as currently in effect.</A></FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DOS</FONT></TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-251427</FONT></TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 19, 2016</FONT></TD>
      </TR>
    <TR STYLE="background-color: White">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD>
      <TD COLSPAN="4">&nbsp;</TD>
      <TD COLSPAN="4">&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1677077/000110465921063812/tm2039434d6_ex3-2.htm">Amended and Restated Bylaws of the Registrant, as currently in effect.</A></FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-255955</FONT></TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 10, 2021</FONT></TD>
      </TR>
    <TR STYLE="background-color: White">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD>
      <TD COLSPAN="4">&nbsp;</TD>
      <TD COLSPAN="4">&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex4_3.htm" STYLE="-sec-extract: exhibit">Form of Common Stock certificate of Registrant.</A></FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      </TR>
    <TR STYLE="background-color: White">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD>
      <TD COLSPAN="4">&nbsp;</TD>
      <TD COLSPAN="4">&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex5_1.htm" STYLE="-sec-extract: exhibit">Opinion of Olshan Frome Wolosky LLP</A></FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      </TR>
    <TR STYLE="background-color: White">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD>
      <TD COLSPAN="4">&nbsp;</TD>
      <TD COLSPAN="4">&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><A HREF="ex23_1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Baker Tilly US, LLP</FONT></A></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      </TR>
    <TR STYLE="background-color: White">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD>
      <TD COLSPAN="4">&nbsp;</TD>
      <TD COLSPAN="4">&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex5_1.htm" STYLE="-sec-extract: exhibit">Consent of Olshan Frome Wolosky LLP (included in Exhibit 5.1)</A></FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      </TR>
    <TR STYLE="background-color: White">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD>
      <TD COLSPAN="4">&nbsp;</TD>
      <TD COLSPAN="4">&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#poa">Power of Attorney (included on the signature page of this Form&nbsp;S-8).</A></FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      </TR>
    <TR STYLE="background-color: White">
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99_1.htm" STYLE="-sec-extract: exhibit">2016 Amended and Restated Stock Incentive Plan</A></FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      </TR>
    <TR STYLE="background-color: White">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD>
      <TD COLSPAN="4">&nbsp;</TD>
      <TD COLSPAN="4">&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99_2.htm" STYLE="-sec-extract: exhibit">2021 Stock Incentive Plan</A></FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      </TR>
    <TR STYLE="background-color: White">
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top">99.3*</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><A HREF="ex99_3.htm" STYLE="-sec-extract: exhibit">Form of 2019 Option Grants</A></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top">99.4*</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><A HREF="ex99_4.htm">Form of 2021 Option Grants</A></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">*</FONT></TD>
      <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Filed herewith.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 20 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR STYLE="clear: both"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9. Undertakings.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. The undersigned Registrant hereby undertakes:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">1. To file, during any period
  in which offers or sales are being made, a post-effective amendment to this Registration Statement:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">(i)&nbsp;To include any prospectus
  required by section 10(a)(3)&nbsp;of the Securities Act;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">(ii)&nbsp;To reflect in the
  prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment
  thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement.
  Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered
  would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be
  reflected in the form of prospectus filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;if, in the aggregate, the changes in volume
  and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration
  Fee&rdquo; table in the effective Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">(iii)&nbsp;To include any
  material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change
  to such information in the Registration Statement;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Provided, however,</I>&nbsp;that
  paragraphs (A)(1)(i)&nbsp;and (A)(1)(ii)&nbsp;do not apply if the information required to be included in a post-effective amendment by
  those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section&nbsp;13 or section&nbsp;15(d)&nbsp;of
  the Exchange Act that are incorporated by reference in the Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">2. That, for the purpose
  of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement
  relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide
  offering thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">3. To remove from registration
  by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. The undersigned Registrant hereby undertakes
  that, for purposes of determining any liability under the Securities Act, each filing of the Registrant&rsquo;s annual report pursuant
  to Section&nbsp;13(a)&nbsp;or Section&nbsp;15(d)&nbsp;of the Exchange Act (and, where applicable, each filing of an employee benefit plan&rsquo;s
  annual report pursuant to section 15(d)&nbsp;of the Exchange Act) that is incorporated by reference in the Registration Statement shall
  be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time
  shall be deemed to be the initial bona fide offering thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">C. Insofar as indemnification for liabilities
  arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing
  provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification
  is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
  against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
  person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
  person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been
  settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
  public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>
  
  <!-- Field: Page; Sequence: 21 -->
      <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
  Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for
  filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in the City of Tampa, State of Florida, on July 13, 2021.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ALZAMEND NEURO, INC.</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 40%">&nbsp;</TD>
      <TD STYLE="width: 4%">&nbsp;</TD>
      <TD STYLE="width: 56%">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
      <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ STEPHAN JACKMAN</I></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephan Jackman</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer (Principal Executive Officer)</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: <I>&nbsp;</I></FONT></TD>
      <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ LIEN T. ESCALONA</I></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lien T. Escalona</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer (Principal Financial and Accounting Officer)</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="poa"></A>POWER OF ATTORNEY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">KNOW ALL PERSONS BY THESE PRESENTS, that each
  person whose signature appears below hereby constitutes and appoints Stephan Jackman and Henry C.W. Nisser, and each of them, as his true
  and lawful attorneys-in-fact and agents, with full power of substitution, for him in any and all capacities, to sign any or all amendments
  to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto, and
  other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents
  full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as
  fully for all intents and purposes as he might or could do in person, hereby and about the premises hereby ratifying and confirming all
  that said attorneys-in-fact and agent, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
  Act of 1933, as amended, the following persons in the capacities and on the dates indicated have signed this Registration Statement below.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR>
      <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; width: 28%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
      <TD STYLE="border-bottom: Black 1pt solid; width: 6%; text-align: justify">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; width: 42%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
      <TD STYLE="border-bottom: Black 1pt solid; width: 6%; text-align: justify">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; width: 18%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>/s/ STEPHAN JACKMAN&nbsp;</I></P></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Executive Officer (Principal Executive
  Officer)&nbsp;and Director</P></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">July 13, 2021</P></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">Stephan Jackman</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>/s/ LIEN T. ESCALONA&nbsp;</I></P></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Financial Officer (Principal Financial
  Officer and Principal Accounting Officer)</P></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 13, 2021</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">Lien T. Escalona</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>/s/ WILLIAM B. HORNE&nbsp;</I></P></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 13, 2021</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">William B. Horne</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>/s/ HENRY C.W. NISSER&nbsp;</I></P></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 13, 2021</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">Henry C.W. Nisser</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>/s/ MARK GUSTAFSON</I></P></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director</P></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 13, 2021</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">Mark Gustafson</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>/s/ LYNNE F. MCGRATH</I></P></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 13, 2021</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">Lynne F. McGrath</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>/s/ JEFFREY ORAM</I></P></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director</P></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 13, 2021</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">Jeffrey Oram</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>/s/ ANDREW H. WOO</I></P>
  
  
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 13, 2021</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">Andrew H. Woo</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  <P STYLE="margin: 0"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "j712211s8.htm", "secsgml_size_bytes": 234508}]
metadata_filer: {"company-data": {"conformed-name": "Alzamend Neuro, Inc.", "cik": "0001677077", "assigned-sic": "2834", "irs-number": "811822909", "state-of-incorporation": "DE", "fiscal-year-end": "0430"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-257873", "film-number": "211088517"}, "business-address": {"street1": "3802 SPECTRUM BLVD,", "street2": "SUITE C112C", "city": "TAMPA", "state": "FL", "zip": "33612", "phone": "844-722-6333"}, "mail-address": {"street1": "3802 SPECTRUM BLVD,", "street2": "SUITE C112C", "city": "TAMPA", "state": "FL", "zip": "33612"}}
text: As filed with the Securities and Exchange Commission
  on July 13, 2021
  Registration No. 333-________
  UNITED STATES
  SECURITIES AND
  EXCHANGE COMMISSION
  Washington, D.C.
  20549
  FORM S-8
  REGISTRATION STATEMENT UNDER THE SECURITIES
  ACT OF 1933
  Alzamend Neuro,
  Inc.
  (Exact name of registrant as specified in its charter)
  Delaware
  (State or other jurisdiction of
  incorporation or organization)
  81-1822909
  (I.R.S. Employer
  Identification No.)
  3802 Spectrum Boulevard, Suite 112C
  Tampa, Florida 33612
  (Address of Principal Executive Offices) (Zip Code)
  2016 Amended and Restated Stock Incentive Plan
  2021 Stock Incentive Plan
  Option Award Agreements
  (Full title of the plans)
  Stephan Jackman, Chief Executive Officer
  Alzamend Neuro, Inc.
  3802 Spectrum Boulevard, Suite 112C
  Tampa, Florida 33612
  (Name and address of agent for service)
  (844) 722-6333
  (Telephone number, including area code, of agent
  for service)
  It is requested that copies of notices and communications
  from the Securities and Exchange Commission be sent to:
  ​
  Spencer G. Feldman, Esq.
  Kenneth A. Schlesinger, Esq.
  Olshan Frome Wolosky LLP
  1325 Avenue of the Americas, 15th Floor
  New York, NY 10019
  Tel.: (212) 451-2300
  ​
  Henry C.W. Nisser, Esq.
  Executive Vice President & General Counsel
  Alzamend Neuro, Inc.
  100 Park Avenue, Suite 1658
  New York, NY 10017
  Tel.: (646) 650-5044
  Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
  See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company,"
  and "emerging growth company" in Rule 12b-2 of the Exchange Act.
  Large accelerated filer
  o
  Accelerated filer
  o
  Non-accelerated filer
  x
  Smaller reporting company
  x
  ​
  Emerging growth company
  x
  If an emerging
  growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
  new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
  o
  CALCULATION OF REGISTRATION FEE
  Title of Securities
  to be Registered
  Amount to be
  Registered (1)
  Proposed
  Maximum Offering
  Price Per Share
  Proposed
  Maximum
  Aggregate Offering
  Price
  Amount of
  Registration Fee
  Common Stock, $0.0001 par value
  19,550,000 (2)
  $0.78 (3)
  $15,249,000
  $1,663.67
  Common Stock, $0.0001 par value
  500,000 (5)
  $6.18 (6)
  $3,090,000
  $337.12
  Common Stock, $0.0001 par value
  5,900,000 (7)
  $1.70 (3)
  $10,030,000
  $1,094.27
  Common Stock, $0.0001 par value
  450,000 (8)
  $6.18 (6)
  $2,781,000
  $303.41
  Common Stock, $0.0001 par value
  9,500,000 (9)
  $6.18 (6)
  $58,710,000
  $6,405.26
  TOTAL
  35,900,000
  $89,860,000
  $9,803.73
  (1)
  This Registration Statement also registers an indeterminable number of additional securities to be offered or issued upon adjustments or changes made to registered securities by reason of any stock splits, stock dividends or similar transactions as permitted by Rule 416(a) and Rule 416(b) under the Securities Act of 1933, as amended, or the Securities Act.
  (2)
  Represents shares of common stock issuable pursuant to stock option awards outstanding under the 2016 Amended and Restated Stock Incentive Plan (the "
  2016 Plan
  ").
  (3)
  Estimated pursuant to Rule 457(h) solely for purposes of calculating the aggregate offering price and the amount of the registration fee based upon a weighted average of the exercise prices of outstanding options previously granted.
  (4)
  Represents shares of common stock issuable pursuant to stock option awards outstanding under the 2021 Stock Incentive Plan (the "
  2021 Plan
  ").
  (5)
  Represents shares of restricted stock issued upon settlement of restricted stock units issued under the 2021 Plan.
  (6)
  Estimated pursuant to Rule 457(c) and (h) solely for purposes of calculating the aggregate offering price and the amount of the registration fee based upon the average of the high and low prices reported for the shares on The Nasdaq Capital Market on July 8, 2021.
  (7)
  Represents shares of common stock issuable pursuant to stock option agreements outside of the 2016 Plan and 2021 Plan.
  (8)
  Represents shares of common stock reserved for future issuance pursuant to the 2016 Plan.
  (9)
  Represents shares of common stock reserved for future issuance pursuant to the 2021 Plan.
  EXPLANATORY NOTE
  This Registration Statement on Form S-8 (this
  "
  Registration Statement
  ") is being filed by Alzamend Neuro, Inc., a Delaware corporation (the "
  Company
  "),
  relating to (i) 19,550,000 shares of common stock, par value $0.0001 per share (the "
  Common Stock
  "), issuable upon
  the exercise of stock options granted under the Alzamend Neuro, Inc. 2016 Amended and Restated Stock Incentive Plan (the "
  2016
  Plan
  "); (ii) 500,000 restricted shares of Common Stock issued under the Alzamend Neuro, Inc. 2021 Stock Incentive Plan (the
  "
  2021 Plan
  "); (iii) 450,000 shares of Common Stock available for issuance under the 2016 Plan; (iv) 9,500,000 shares
  of Common Stock available for issuance under the 2021 Plan; and (v) 5,900,000 shares of Common Stock issuable upon the exercise of stock
  options granted to certain employees pursuant to option agreements outside of the 2016 Plan and 2021 Plan (the "
  Option Agreements
  ",
  and together with the 2016 Plan and the 2021 Plan, the "
  Plans
  ").
  This Registration Statement also includes a prospectus
  (the "
  Reoffer Prospectus
  ") prepared in accordance with General Instruction C of Form S-8 and in accordance with the
  requirements of Part I of Form S-3. This Reoffer Prospectus may be used for the reoffer and resale of shares of Common Stock on a continuous
  or delayed basis that may be deemed to be "restricted securities" and/or "control securities" within the meaning
  of the Securities Act of 1933, as amended (the "
  Securities Act
  "), and the rules and regulations promulgated thereunder,
  that are issuable to certain of our executive officers, employees, consultants and directors identified in the Reoffer Prospectus. The
  number of shares of Common Stock included in the Reoffer Prospectus represents shares of Common Stock issuable to the selling stockholders
  pursuant to equity awards, including stock options and restricted stock grants, granted to the selling stockholders and does not necessarily
  represent a present intention to sell any or all such shares of Common Stock. The number of shares of Common Stock to be offered or resold
  by means of the Reoffer Prospectus by the selling stockholders, and any other person with whom any of them is acting in concert for the
  purpose of selling Common Stock, may not exceed, during any three month period, the amount specified in Rule 144(e) under the Securities
  Act.
  As specified in General Instruction C of Form
  S-8, until such time as we meet the registrant requirements for use of Form S-3, the number of shares of Common Stock to be offered by
  means of this reoffer prospectus, by each of the selling securityholders, and any other person with whom he or she is acting in concert
  for the purpose of selling our shares of Common Stock, may not exceed, during any three month period, the amount specified in Rule 144(e)
  of the Securities Act.
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
  Item 1.
  Plan Information.
  The Company will provide each recipient of a grant
  under the Plans (the "
  Recipients
  ") with documents that contain information related to the Plans, and other information
  including, but not limited to, the disclosure required by Item 1 of Form S-8, which information is not required to be and is not being
  filed as a part of this Registration Statement on Form S-8 (the "
  Registration Statement
  ") or as prospectuses or prospectus
  supplements pursuant to Rule 424 under the Securities Act. The foregoing information and the documents incorporated by reference in response
  to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a)
  of the Securities Act. A Section 10(a) prospectus will be given to each Recipient who receives shares of Common Stock covered by this
  Registration Statement, in accordance with Rule 428(b)(1) under the Securities Act.
  Item 2.
  Registrant Information and Employee Plan Annual Information.
  We will provide to each Recipient a written statement
  advising of the availability of documents incorporated by reference in Item 3 of Part II of this Registration Statement (which documents
  are incorporated by reference in this Section 10(a) prospectus) and of documents required to be delivered pursuant to Rule 428(b) under
  the Securities Act without charge and upon written or oral request by contacting:
  Henry C.W. Nisser, Esq.
  Executive Vice President & General Counsel
  Alzamend Neuro, Inc.
  100 Park Avenue, Suite 1658
  New York, NY 10017
  REOFFER PROSPECTUS
  25,950,000 Shares
  Common Stock
  Issuable under certain awards
  granted under the Plans
  This reoffer prospectus relates
  to the public resale, from time to time, of an aggregate of 25,950,000 shares (the "
  Shares
  ") of our common stock, $0.0001
  par value per share (the "
  Common Stock
  ") by certain securityholders identified herein in the section entitled "Selling
  Securityholders". Such shares may be acquired in connection with awards granted under the Alzamend Neuro, Inc. (the "
  Company
  ")
  2016 Amended and Restated Stock Incentive Plan (the "
  2016 Plan
  "), the Company's 2021 Stock Incentive Plan (the
  "
  2021 Plan
  ") and stock options granted to certain employees pursuant to option agreements outside of the Plans ("
  Option
  Agreements
  " and collectively with the 2016 Plan and the 2021 Plan, the "
  Plans
  "). You should read this prospectus
  carefully before you invest in our Common Stock.
  Such resales shall take place
  on The Nasdaq Capital Market, or such other stock market or exchange on which our Common Stock may be listed or quoted, in negotiated
  transactions or otherwise, at market prices prevailing at the time of the sale or at prices otherwise negotiated (see "Plan of Distribution"
  starting on page 9 of this prospectus). We will receive no part of the proceeds from sales made under this reoffer prospectus. The Selling
  Securityholders will bear all sales commissions and similar expenses. Any other expenses incurred by us in connection with the registration
  and offering and not borne by the Selling Securityholders will be borne by us.
  This reoffer prospectus has
  been prepared for the purposes of registering our shares of Common Stock under the Securities Act to allow for future sales by Selling
  Securityholders on a continuous or delayed basis to the public without restriction, provided that the amount of shares of Common Stock
  to be offered or resold under this Reoffer Prospectus by each Selling Securityholder or other person with whom he or she is acting in
  concert for the purpose of selling shares of Common Stock, may not exceed, during any three-month period, the amount specified in Rule
  144(e) under the Securities Act. We have not entered into any underwriting arrangements in connection with the sale of the shares covered
  by this reoffer prospectus. The Selling Securityholders identified in this reoffer prospectus, or their pledgees, donees, transferees
  or other successors-in-interest, may offer the shares covered by this reoffer prospectus from time to time through public or private transactions
  at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices.
  Investing in our Common Stock
  involves risks. See "Risk Factors" beginning on page 3 of this reoffer prospectus. These are speculative securities.
  Our Common Stock is quoted
  on The Nasdaq Capital Market under the symbol "ALZN" and the last reported sale price of our Common Stock on July 12, 2021
  was $6.11 per share.
  NEITHER THE SECURITIES
  AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS
  IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
  The date of this prospectus is July 13, 2021
  ALZAMEND NEURO, INC.
  TABLE OF CONTENTS
  Page
  Cautionary Statement Regarding Forward-Looking Statements
  i
  Prospectus Summary
  1
  Risk Factors
  3
  Use of Proceeds
  5
  Selling Securityholders
  6
  Plan of Distribution
  9
  Legal Matters
  10
  Experts
  10
  Incorporation of Certain Documents by Reference
  10
  Disclosure of Commission Position on Indemnification For Securities Act Liabilities
  10
  Where You can Find Additional Information
  11
  Except where the context
  otherwise requires, the terms, "we," "us," "our" or "the Company," refer to the business
  of Alzamend Neuro, Inc., a Delaware corporation.
  CAUTIONARY STATEMENT
  REGARDING FORWARD-LOOKING STATEMENTS
  This prospectus, including
  the documents that we incorporate by reference, contains forward-looking statements. All statements other than statements of historical
  fact are, or may be deemed to be, forward-looking statements. Such forward-looking statements include statements regarding, among others,
  (a) our expectations about possible business combinations, (b) our growth strategies, (c) our future financing plans, and
  (d) our anticipated needs for working capital. Forward-looking statements, which involve assumptions and describe our future plans,
  strategies, and expectations, are generally identifiable by use of the words "may," "will," "should,"
  "expect," "anticipate," "approximate," "estimate," "believe," "intend,"
  "plan," "budget," "could," "forecast," "might," "predict," "shall"
  or "project," or the negative of these words or other variations on these words or comparable terminology. This information
  may involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements
  to be materially different from the future results, performance, or achievements expressed or implied by any forward-looking statements.
  These statements may be found in this prospectus, including the documents that we incorporate by reference.
  Forward-looking statements
  are based on our current expectations and assumptions regarding our business, potential target businesses, the economy and other future
  conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks,
  and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking
  statements as a result of various factors, including, without limitation, changes in local, regional, national or global political, economic,
  business, competitive, market (supply and demand) and regulatory conditions and the following:
  •
  our ability to effectively execute our business strategy;
  •
  our ability to manage our expansion, growth and operating expenses;
  •
  our ability to evaluate and measure our business, prospects and performance metrics;
  •
  our ability to compete and succeed in a highly competitive and evolving industry;
  •
  our ability to respond and adapt to changes in technology and customer behavior;
  •
  our ability to protect our intellectual property and to develop, maintain and enhance a strong brand;
  •
  our significant losses since inception and anticipation that we will continue to incur significant losses for the foreseeable future;
  •
  our need for substantial additional funding to finance our operations and complete development to seek U.S. Food and Drug Administration ("
  FDA
  ") approval for AL001 and AL002 before commercialization;
  •
  our reliance on licenses from a third party regarding our rights and development of AL001 and AL002;
  •
  our development of AL001 and AL002 never leading to a marketable product;
  •
  our product candidates not qualifying for expedited development, or if they do, not actually leading to a faster development or regulatory review or approval process; and
  •
  our approach to targeting beta-amyloid plaque via AL002 being based on a novel therapeutic approach.
  We caution you therefore that
  you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future
  performance.
  Information regarding market
  and industry statistics contained in this prospectus, including the documents that we incorporate by reference, is included based on information
  available to us that we believe is accurate. It is generally based on academic and other publications that are not produced for purposes
  of securities offerings or economic analysis. Forecasts and other forward-looking information obtained from these sources are subject
  to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance
  of products and services. Except as required by U.S. federal securities laws, we have no obligation to update forward-looking information
  to reflect actual results or changes in assumptions or other factors that could affect those statements.
  i
  PROSPECTUS SUMMARY
  The Commission allows us to ''incorporate
  by reference'' certain information that we file with the Commission, which means that we can disclose important information
  to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus, and
  information that we file later with the Commission will update automatically, supplement and/or supersede the information disclosed in
  this prospectus. Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus shall
  be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or
  in any other document that also is or is deemed to be incorporated by reference in this prospectus modifies or supersedes such statement.
  Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
  You should read the following summary together with the more detailed information regarding our company, our Common Stock and our financial
  statements and notes to those statements appearing elsewhere in this prospectus or incorporated herein by reference.
  Our Company
  We are a preclinical stage
  biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders.
  With our two current and future product candidates, we aim to bring treatments or cures to market at a reasonable cost as quickly as possible.
  Far too many individuals — patients and caregivers — suffer from the burden created by these devastating,
  and often fatal, diseases. Our primary target, Alzheimer's Disease, was among the most-feared diseases (second only to cancer) among
  Americans, according to a 2011 survey by the Harvard School of Public Health. Alzheimer's is also the sixth leading cause of death
  in the United States according to a 2021 report from the Alzheimer's Association, a nonprofit that funds research. Existing Alzheimer's
  treatments only temporarily relieve symptoms but do not slow or halt the underlying worsening of the disease, which currently affects
  roughly 6.2 million Americans and that number is expected to grow to 13 million individuals by 2050. Alzheimer's also
  impacts more than 11 million Americans who provide an estimated 15.3 billion hours of unpaid care per year, valued at $257 billion,
  according to data provided by the Alzheimer's Association. In 2021, the estimated healthcare costs for treating individuals with
  Alzheimer's in the United States will be $355 billion, including $239 billion in Medicare and Medicaid payments. These
  costs could rise to as high as $1.1 trillion per year by 2050 if no permanent treatment or cure for Alzheimer's is found, the Alzheimer's
  Association reported.
  Corporate Information
  We were incorporated on February 26,
  2016 as Alzamend Neuro, Inc. under the laws of the State of Delaware. Our executive offices are located at 3802 Spectrum Blvd., Suite
  112C, Tampa, Florida 33612 and our telephone number is (844) 722-6333. We maintain a corporate website at www.alzamend.com. The information
  on our website is not part of this prospectus. We have included our website address as a factual reference and do not intend it to be
  active link to our website.
  1
  The Offering
  Outstanding Common Stock:
  85,304,525 shares of our Common Stock are outstanding as of July 12, 2021.
  Common Stock Offered:
  Up to 25,950,000 shares of Common Stock for sale by the selling securityholders (which include our executive officers and directors) for their own account pursuant to the Plans.
  Selling Securityholders:
  The selling securityholders are set forth in the section entitled "Selling Securityholders" of this reoffer prospectus on page 6.  The amount of securities to be offered or resold by means of the reoffer prospectus by the designated selling securityholders may not exceed, during any three month period, the amount specified in Rule 144(e).
  Use of proceeds:
  We will not receive any proceeds from the sale of our Common Stock by the selling securityholders. We would, however, receive proceeds upon the exercise of the stock options by those who receive options under the Plans and exercise such options for cash. Any cash proceeds will be used by us for general corporate purposes.
  Risk Factors:
  The securities offered hereby involve a high degree of risk. See "Risk Factors."
  Nasdaq Capital Market trading
  symbol:
  ALZN
  2
  RISK FACTORS
  An investment in shares of our Common Stock is
  highly speculative and involves a high degree of risk. We face a variety of risks that may affect our operations or financial results
  and many of those risks are driven by factors that we cannot control or predict. Before investing in our Common Stock, you should carefully
  consider the risks below and set forth under the caption "Risk Factors" in our Registration Statement on Form S-1, as amended
  (File No. 333-255955), filed with the Securities and Exchange Commission on June 11, 2021, which are incorporated by reference herein,
  and subsequent reports filed with the SEC, together with the financial and other information contained or incorporated by reference in
  this prospectus. If any of these risks actually occurs, our business, prospects, financial condition and results of operations could be
  materially adversely affected. In that case, the trading price of our Common Stock would likely decline and you may lose all or a part
  of your investment. Only those investors who can bear the risk of loss of their entire investment should invest in our Common Stock.
  Risks Relating to Ownership of Our Common Stock
  Our stock price may be volatile, and the
  value of our Common Stock may decline.
  The market price of our Common
  Stock may be highly volatile and may fluctuate or decline substantially as a result of a variety of factors, some of which are beyond
  our control, including:
  •
  announcements of the failure to obtain regulatory approvals or receipt of a "complete response letter" from the FDA;
  •
  announcements of restricted label indications or patient populations, or changes or delays in regulatory review processes;
  •
  announcements of therapeutic innovations or new products by us or our competitors;
  •
  adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing
  activities;
  •
  changes or developments in laws or regulations applicable to our product candidates;
  •
  the failure of our testing and clinical trials;
  •
  the impact of the ongoing COVID-19 pandemic on our business;
  •
  product liability claims, other litigation or public concern about the safety of our product candidates or future products;
  •
  any adverse changes to our relationship with licensors, manufacturers or suppliers;
  •
  the loss of any of our key scientific or management personnel;
  •
  any major changes in our Board of Directors or management;
  •
  the failure to obtain new commercial partners;
  •
  announcements concerning our competitors or the pharmaceutical industry in general;
  •
  the failure to achieve expected product sales and profitability;
  •
  the failure to obtain reimbursements for our product candidates as part of any healthcare insurance plan, or reductions in such reimbursements;
  •
  actual or anticipated fluctuations in our cash position or operating results;
  •
  manufacturing, supply or distribution shortages related to our current or future product candidates for our development programs and
  commercialization;
  •
  changes in financial estimates or recommendations by securities analysts;
  3
  •
  the termination of any of our existing license agreements;
  •
  announcements relating to future licensing or development agreements;
  •
  potential acquisitions;
  •
  the trading volume of shares on The Nasdaq Capital Market;
  •
  sales of our shares by us, our executive officers or directors or our shareholders;
  •
  fluctuations in the U.S. equity markets;
  •
  changes in accounting principles;
  •
  market conditions in the healthcare sector; and
  •
  general economic conditions in the United States and elsewhere.
  In recent years, each
  of the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant
  price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies
  whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price
  of our Common Stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market
  for our Common Stock shortly following this offering. Following periods of such volatility in the market price of a company's securities,
  securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price,
  we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management's
  attention and resources from our business.
  A significant portion of our total outstanding
  shares is restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our
  Common Stock to decline significantly, even if our business is doing well.
  Sales of a substantial number
  of shares of our Common Stock in the public market could occur at any time. These sales, upon the expiration of any or all of the lock-up
  agreements entered into between the representative and each of our directors, executive officers and substantially all holders of more
  than 5% of our outstanding Common Stock, as well as certain other parties (the "lock-up agreements"), the early release from
  these agreements or the perception in the market that the holders of a large number of shares of our Common Stock intend to sell shares,
  could cause the market price of our Common Stock to fall and could impair our ability to raise capital by selling additional securities.
  As of July 12, 2021, we have 85,304,525 shares of Common Stock outstanding. Of these shares, 2,875,000 shares that were sold in our initial
  public offering are freely tradable without restriction or further registration under the Securities Act, except for any shares purchased
  by holders subject to lock-up agreements or by any of our affiliates within the meaning of Rule 144 under the Securities Act, which generally
  includes executive officers, directors and 10% stockholders. Of the 85,304,525 shares of our Common Stock outstanding, a significant amount
  of them are locked-up as a result of the lock-up agreements that existing stockholders have signed restricting their ability to transfer
  our stock for 180 days after June 14, 2021. Certain of these holders will be subject to a lock-up agreement that will allow them to sell,
  beginning 90 days after June 14, 2021 (the "Leak-Out Period Commencement Date"), up to 33.3% of their shares and any other
  Locked-Up Securities (as defined herein) in any rolling 30-day period, with a daily cap of 10% of the traded volume on Nasdaq. Holders
  subject to this version of the lock-up agreement will be released from such lock-up upon the earlier of (i) the 90th day after the
  Leak-Out Period Commencement Date and (ii) the meeting of certain stock price and trading volume thresholds, which release would
  be no earlier than the 10th trading day after the Leak-Out Period Commencement Date. Substantially all of the remaining shares, held by
  persons who are not deemed to be affiliates (at the time of or at any time during the three months preceding a sale), were either sold
  by us in a Regulation A offering and are freely transferable or are restricted securities under Rule 144, in that they were issued in
  private transactions not involving a public offering, and have been beneficially owned for at least one year. All of these remaining shares
  are currently eligible for sale. In addition, the potential future exercise of warrants and stock options to purchase our Common Stock
  and conversion of convertible debt instruments into our Common Stock could result in our issuing a significant number of additional shares
  of Common Stock. Pursuant to this prospectus, we are registering all shares of Common Stock that we may issue under our stock incentive
  plans, which can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates
  and the lock-up agreements described above. If any of these additional shares are sold, or if it is perceived that they will be sold,
  in the public market, the market price of our Common Stock could decline significantly, even if our business is doing well.
  4
  We may fail to meet our publicly announced
  guidance or other expectations about our business, which would cause our stock price to decline.
  We expect to provide guidance
  regarding our expected financial and business performance, such as projections regarding sales and product development, as well as anticipated
  future revenues, gross margins, profitability and cash flows. Correctly identifying key factors affecting business conditions and predicting
  future events is inherently an uncertain process and our guidance may not be accurate. Our guidance is based on certain assumptions such
  as those relating to anticipated FDA approval for our product candidates, the results of our clinical trials, the marketing of any of
  our product candidates, among many other factors. If our guidance is not accurate or varies from actual results due to our inability to
  meet our assumptions or the impact on our financial performance that could occur as a result of various risks and uncertainties, the market
  value of our Common Stock could decline significantly.
  Our issuance of additional capital stock
  in connection with financings, acquisitions, investments, our equity incentive plans or otherwise will dilute all other stockholders.
  We
  expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect to grant equity
  awards to employees, directors and consultants under our equity incentive plans. We may also raise capital through equity financings in
  the future. As part of our business strategy, we may acquire or make investments in companies, products or technologies and issue equity
  securities to pay for any such acquisition or investment. Any such issuances of additional capital stock may cause stockholders to experience
  significant dilution of their ownership interests and the per share value of our Common Stock to decline.
  Because we do not intend to pay dividends
  on our Common Stock, you must rely on stock appreciation for any return on your investment.
  We presently intend to retain
  any future earnings and do not expect to pay any dividends in the foreseeable future. As a result, you must rely on stock appreciation
  and a liquid trading market for any return on your investment. If an active and liquid trading market does not develop, you may be unable
  to sell your shares of Common Stock at a price above which you paid for your shares.
  If securities analysts do not publish research
  or reports about our business or if they publish negative evaluations of our stock, the price of our Common Stock could decline.
  The trading market for our
  Common Stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. We do
  not currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of
  us, the trading price of our Common Stock could decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering
  our business downgrade their evaluations of our stock, the price of our Common Stock could decline. If one or more of these analysts cease
  to cover our stock, we could lose visibility in the market for our Common Stock, which in turn could cause our stock price to decline.
  USE OF PROCEEDS
  The shares which may be sold
  under this reoffer prospectus will be sold for the respective accounts of each of the Selling Securityholders listed herein (which includes
  our executive officers and directors). Accordingly, we will not realize any proceeds from the sale of the shares of our Common Stock.
  We will receive proceeds from the exercise of the options; however, no assurance can be given as to when or if any or all of the options
  will be exercised. If any options are exercised, the proceeds derived therefrom will be used for working capital and general corporate
  purposes. All expenses of the registration of the shares will be paid by us. See "Selling Securityholders" and "Plan
  of Distribution."
  5
  SELLING SECURITYHOLDERS
  We are registering for resale
  the shares covered by this prospectus to permit the Selling Securityholders identified below and their pledgees, donees, transferees and
  other successors-in-interest that receive their securities from a Selling Securityholder as a gift, partnership distribution or other
  non-sale related transfer after the date of this prospectus to resell the shares when and as they deem appropriate. The Selling Securityholders
  acquired, or may acquire, these shares from us pursuant to the Plans. The shares may not be sold or otherwise transferred by the Selling
  Securityholders unless and until the applicable awards vest and are exercised, as applicable, in accordance with the terms and conditions
  of the Plans.
  The following table sets forth:
  ·
  the name of each Selling Securityholder;
  ·
  the position(s), office or other material relationship with our company and its predecessors or affiliates, over the last three years of each Selling Securityholder;
  ·
  the number and percentage of shares of our Common Stock that each Selling Securityholder beneficially owned as of July 12, 2021 prior to the offering for resale of the shares under this prospectus;
  ·
  the number of shares of our Common Stock that may be offered for resale for the account of each Selling Securityholder under this prospectus; and
  ·
  the number and percentage of shares of our Common Stock to be beneficially owned by each Selling Securityholder after the offering of the resale shares (assuming all of the offered resale shares are sold by such Selling Securityholder).
  Information with respect to
  beneficial ownership is based upon information obtained from the Selling Securityholders.  Because the Selling Securityholders
  may offer all or part of the shares of Common Stock, which they own pursuant to the offering contemplated by this reoffer prospectus,
  and because its offering is not being underwritten on a firm commitment basis, no estimate can be given as to the amount of shares that
  will be held upon termination of this offering.
  The number of shares in the
  column ''Number of Shares Being Offered'' represents all of the shares of our Common Stock that each Selling Securityholder
  may offer under this prospectus. We do not know how long the Selling Securityholders will hold the shares before selling them or how many
  shares they will sell. The shares of our Common Stock offered by this prospectus may be offered from time to time by the Selling Securityholders
  listed below. We cannot assure you that any of the Selling Securityholders will offer for sale or sell any or all of the shares of Common
  Stock offered by them by this prospectus.
  Number of Shares Beneficially
  Owned Prior to Offering (1)
  Number
                                              of
  Shares Being
  Number
                                              of Shares Beneficially
  Owned After Offering
  (2)
  Securityholders
  Number
  Percent
  (%)
  Offered
  Number
  Percent (%)
  Milton C. Ault, III (3)
  39,156,055
  41.59
  %
  2,500,000
  36,656,055
  38.93
  %
  Stephan Jackman (4)
  2,062,500
  2.36
  %
  7,000,000
  0
  *
  William B. Horne (5)
  2,645,833
  3.01
  %
  3,000,000
  0
  *
  Henry C.W. Nisser (6)
  729,167
  *
  1,250,000
  0
  *
  Lien T. Escalona (7)
  12,500
  *
  300,000
  0
  *
  Kenneth S. Cragun (8)
  1,000,000
  1.16
  %
  2,500,000
  0
  *
  David Katzoff (9)
  784,292
  *
  2,500,000
  27,000
  *
  Mark Gustafson (10)
  0
  *
  400,000
  0
  *
  Lynne Fahey McGrath (11)
  0
  *
  400,000
  0
  *
  Jeffrey Oram (12)
  0
  *
  400,000
  0
  *
  Andrew H. Woo (13)
  0
  *
  400,000
  0
  *
  Phil Mansour (14)
  2,500,000
  2.85
  %
  2,500,000
  0
  *
  Garry Gottlieb (15)
  1,375,133
  1.60
  %
  1,000,000
  729,300
  *
  Chuanhai Cao (16)
  2,079,148
  2.42
  %
  500,000
  1,620,815
  1.89
  %
  Named Selling Stockholders (17)
  390,064
  *
  1,300,000
  26,001
  *
  *less than 1%
  (1)
  The number and percentage of shares beneficially owned is determined in accordance with Rule 13d-3
  of the Securities Exchange Act of 1934, as amended, and the information is not necessarily indicative of beneficial ownership for any
  other purpose. Under such rule, beneficial ownership includes any shares as to which the Selling Securityholder has sole or shared voting
  power or investment power and also any shares which the Selling Securityholder has the right to acquire within 60 days. Applicable percentage
  ownership is based on 85,304,525 shares of Common Stock outstanding as of July 12, 2021.
  6
  (2)
  Assumes that all shares of Common Stock to be offered, as set forth above, are sold pursuant to this offering
  and that no other shares of Common Stock are acquired or disposed of by the Selling Securityholders prior to the termination of this offering.
  Because the Selling Securityholders may sell all, some or none of their shares of Common Stock or may acquire or dispose of other shares
  of Common Stock, no reliable estimate can be made of the aggregate number of shares of Common Stock that will be sold pursuant to this
  offering or the number or percentage of shares of Common Stock that each Selling Securityholder will own upon completion of this offering.
  (3)
  Mr. Ault is our Founder and Chairman Emeritus. He served as our Executive Chairman from November 2018
  until our initial public offering in June 2021. The shares of Common Stock beneficially owned prior to this offering include 2,500,000
  shares of Common Stock issuable upon exercise of options which are currently exercisable, 15,000,000 shares of Common Stock owned by owned
  by Ault Life Sciences, Inc. ("
  Ault Life Sciences
  "), 10,000,000 shares of Common Stock and 5,000,000 shares of Common
  Stock underlying warrants owned by Ault Life Sciences Fund, LLC ("
  Ault Fund
  "), and 5,306,055 shares of Common Stock
  and 1,350,000 shares of Common Stock underlying warrants owned by Digital Power Lending, LLC ("
  DP Lending
  "). Mr. Ault
  has sole voting and investment power with respect to the securities held of record by Ault Life Sciences and Ault Fund. DP Lending is
  a wholly-owned subsidiary of Ault Global Holdings, Inc. ("
  AGH
  "). Mr. Ault, the Executive Chairman of AGH, is deemed
  to have voting and investment power with respect to the securities held of record by DP Lending. The shares of Common Stock registered
  for resale hereunder represent shares issuable upon exercise of vested stock options.
  (4)
  Mr. Jackman is our Chief Executive Officer and a member of the Board. The shares of Common Stock beneficially
  owned prior to this offering represent shares of Common Stock issuable upon exercise of options which are currently exercisable or become
  exercisable within 60 days. The shares of Common Stock registered for resale hereunder represent shares issuable upon exercise of vested
  and unvested stock options.
  (5)
  Mr. Horne is our Chairman of the Board. The shares of Common Stock beneficially owned prior to this offering
  represent shares of Common Stock issuable upon exercise of options which are currently exercisable or become exercisable within 60 days.
  The shares of Common Stock registered for resale hereunder represent shares issuable upon exercise of vested and unvested stock options.
  (6)
  Mr. Nisser is our Executive Vice President, General Counsel and a member of the Board. The shares of Common
  Stock beneficially owned prior to this offering represent shares of Common Stock issuable upon exercise of options which are currently
  exercisable or become exercisable within 60 days. The shares of Common Stock registered for resale hereunder represent shares issuable
  upon exercise of vested and unvested stock options.
  (7)
  Ms. Escalona is our Chief Financial Officer. The shares of Common Stock registered for resale hereunder
  represent shares issuable upon exercise of unvested stock options.
  (8)
  Mr. Cragun is our Senior Vice President of Finance. The shares of Common Stock beneficially owned prior
  to this offering represent shares of Common Stock issuable upon exercise of options which are currently exercisable or become exercisable
  within 60 days. The shares of Common Stock registered for resale hereunder represent shares issuable upon exercise of vested and unvested
  stock options.
  (9)
  Mr. Katzoff is our Chief Operating Officer. The shares of Common Stock beneficially owned prior to this
  offering include 757,292 shares of Common Stock issuable upon exercise of options which are currently exercisable or become exercisable
  within 60 days and 9,000 shares of Common Stock underlying warrants. The shares of Common Stock registered for resale hereunder represent
  shares issuable upon exercise of vested and unvested stock options.
  (10)
  Mr. Gustafson is a member of the Board. The shares of Common Stock registered for resale hereunder represent
  shares issuable upon exercise of unvested stock options and shares of Common Stock issuable upon settlement of unvested restricted stock
  grants.
  (11)
  Dr. McGrath is a member of the Board. The shares of Common Stock registered for resale hereunder represent
  shares issuable upon exercise of unvested stock options and shares of Common Stock issuable upon settlement of unvested restricted stock
  grants.
  (12)
  Mr. Oram is a member of the Board. The shares of Common Stock registered for resale hereunder represent
  shares issuable upon exercise of unvested stock options and shares of Common Stock issuable upon settlement of unvested restricted stock
  grants.
  (13)
  Dr. Woo is a member of the Board. The shares of Common Stock registered for resale hereunder represent
  shares issuable upon exercise of unvested stock options and shares of Common Stock issuable upon settlement of unvested restricted stock
  grants.
  7
  (14)
  Mr. Mansour was a member of the Board until our initial public offering in June 2021. The shares of Common
  Stock beneficially owned prior to this offering represent shares of Common Stock issuable upon exercise of options which are currently
  exercisable. The shares of Common Stock registered for resale hereunder represent shares issuable upon exercise of vested stock options.
  (15)
  Gary Gottlieb is a former employee of Alzamend. The shares of Common Stock beneficially owned prior to
  this offering include 645,833 shares of Common Stock issuable upon exercise of options which are currently exercisable or become exercisable
  within 60 days and 187,500 shares owned by Buckeye Quad Trust. Mr. Gottlieb, as the Trustee of Buckeye Quad Trust, has investment and
  voting control over the shares held by this entity. The shares of Common Stock registered for resale hereunder represent shares issuable
  upon exercise of vested and unvested stock options.
  (16)
  Chuanhai Cao is a consultant to Alzamend. The shares of Common Stock beneficially owned prior to this
  offering include 458,333 shares of Common Stock issuable upon exercise of options which are currently exercisable or become exercisable
  within 60 days. The shares of Common Stock registered for resale hereunder represent shares issuable upon exercise of vested and unvested
  stock options.
  (17)
  Includes the following 16 named non-affiliate persons, each of whom beneficially owns at least
  1,000 Shares: Sonsorey Corbin; Eve del Rio; Therese Doherty; Laura Kim; Eric McDade; Donald Reitberg; Michael Rooney; Kenny Seaver; Arthur
  Spalding; Georgia Thompson; James M. Turner; Kirk Van Ness; Janan Van Osdell; Brianna Wharton; Thomas Wisniewski; and Gary Wolfe.
  Each
  of these persons beneficially owns less than 1% of our Common Stock.
  8
  PLAN OF DISTRIBUTION
  We
  are registering the Shares covered by this prospectus to permit the Selling Stockholders to conduct public secondary trading of these
  Shares from time to time after the date of this prospectus. We will not receive any of the proceeds of the sale of the Shares offered
  by this prospectus. The aggregate proceeds to the Selling Stockholders from the sale of the Shares will be the purchase price of the Shares
  less any discounts and commissions. We will not pay any brokers' or underwriters' discounts and commissions in connection
  with the registration and sale of the Shares covered by this prospectus. The Selling Stockholders reserve the right to accept and, together
  with their respective agents, to reject, any proposed purchases of Shares to be made directly or through agents.
  The Shares offered by
  this prospectus may be sold from time to time to purchasers:
  •
  directly by the Selling Stockholders, or
  •
  through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, commissions or agent's commissions from the Selling Stockholders or the purchasers of the Shares.
  Any
  underwriters, broker-dealers or agents who participate in the sale or distribution of the Shares may be deemed to be "underwriters"
  within the meaning of the Securities Act. As a result, any discounts, commissions or concessions received by any such broker-dealer or
  agents who are deemed to be underwriters will be deemed to be underwriting discounts and commissions under the Securities Act. Underwriters
  are subject to the prospectus delivery requirements of the Securities Act and may be subject to certain statutory liabilities under the
  Securities Act and the Securities Exchange Act of 1934, as amended (the "Exchange Act"). We will make copies of this prospectus
  available to the Selling Stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. To our
  knowledge, there are currently no plans, arrangements or understandings between the Selling Stockholders and any underwriter, broker-dealer
  or agent regarding the sale of the Shares by the Selling Stockholders.
  The Shares may be sold
  in one or more transactions at:
  •
  fixed prices;
  •
  prevailing market prices at the time of sale;
  •
  prices related to such prevailing market prices;
  •
  varying prices determined at the time of sale; or
  •
  negotiated prices.
  These sales may be effected
  in one or more transactions:
  •
  on any national securities exchange or quotation service on which the Shares may be listed or quoted at the time of sale, including the NYSE;
  •
  in the over-the-counter market;
  •
  in transactions otherwise than on such exchanges or services or in the over-the-counter market;
  •
  any other method permitted by applicable law; or
  •
  through any combination of the foregoing.
  These
  transactions may include block transactions or crosses. Crosses are transactions in which the same broker acts as an agent on both sides
  of the trade.
  At
  the time a particular offering of the Shares is made, a prospectus supplement, if required, will be distributed, which will set forth
  the name of the Selling Stockholders, the aggregate amount of Shares being offered and the terms of the offering, including, to the extent
  required, (1) the name or names of any underwriters, broker-dealers or agents, (2) any discounts, commissions and other terms
  constituting compensation from the Selling Stockholders and (3) any discounts, commissions or concessions allowed or reallowed to
  be paid to broker-dealers.
  The
  Selling Stockholders will act independently of us in making decisions with respect to the timing, manner, and size of each resale or other
  transfer. There can be no assurance that the Selling Stockholders will sell any or all of the Shares under this prospectus. Further, we
  cannot assure you that the Selling Stockholders will not transfer, distribute, devise or gift the Shares by other means not described
  in this prospectus. In addition, any Shares covered by this prospectus that qualify for sale under Rule 144 of the Securities Act may
  be sold under Rule 144 rather than under this prospectus. The Shares may be sold in some states only through registered or licensed brokers
  or dealers. In addition, in some states the Shares may not be sold unless they have been registered or qualified for sale or an exemption
  from registration or qualification is available and complied with.
  9
  The
  Selling Stockholders and any other person participating in the sale of the Shares will be subject to the Exchange Act. The Exchange Act
  rules include, without limitation, Regulation M, which may limit the timing of purchases and sales of any of the Shares by the Selling
  Stockholders and any other person. In addition, Regulation M may restrict the ability of any person engaged in the distribution of the
  Shares to engage in market-making activities with respect to the particular Shares being distributed. This may affect the marketability
  of the Shares and the ability of any person or entity to engage in market-making activities with respect to the Shares.
  The
  Selling Stockholders may indemnify any broker or underwriter that participates in transactions involving the sale of the Shares against
  certain liabilities, including liabilities arising under the Securities Act.
  LEGAL MATTERS
  The validity of the issuance
  of the securities offered by this prospectus will be passed upon for us by Olshan Frome Wolosky LLP, New York, New York.
  EXPERTS
  The financial statements of
  Alzamend Neuro, Inc. as of April 30, 2020 and 2019 and for each of the two years in the period ended April 30, 2020 incorporated by reference
  in this Prospectus and Registration Statement from the Company's Registration Statement on form S-1 (No. 333-255955), as amended,
  have been audited by Squar Milner LLP (which effective as of November 1, 2020, merged with Baker Tilly US, LLP), an independent registered
  public accounting firm, as stated in their report thereon (which report expresses an unqualified opinion and includes an explanatory paragraph
  relating to the Company's ability to continue as a going concern), incorporated herein by reference, and have been incorporated
  in this Prospectus and Registration Statement in reliance upon such report and upon the authority of such firm as experts in accounting
  and auditing.
  INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
  The following documents filed
  with the SEC are hereby incorporated by reference in this prospectus (unless otherwise noted, the SEC file number for each of the documents
  listed below is 001-40483):
  ·
  Amendment No. 4 to the Registrant's Registration Statement on Form S-1 filed with the Securities and Exchange Commission on June 11, 2021 (File No. 333-255955), which contains the Registrant's audited financial statements for the latest fiscal year for which such statements have been filed
  ·
  The Registrant's Prospectus filed on June 15, 2021 pursuant to Rule 424(b) under the Securities Act, relating to the Registration Statement on Form S-1, as amended (File No. 333-255955).
  ·
  Current Report on Form 8-K filed on June 22, 2021; and
  ·
  The description of the Registrant's Common Stock which is contained in a registration statement on Form 8-A filed on June 11, 2021 under the Exchange Act, including any amendment or report filed for the purpose of updating such description.
  All documents filed by the
  Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and
  prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been
  sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement
  and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been
  furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement.
  Any statement contained in
  a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of
  this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed
  to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be
  deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
  DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION
  FOR SECURITIES ACT LIABILITIES
  Insofar as indemnification
  for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the registrant, the registrant
  has been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act
  and is therefore unenforceable.
  10
  WHERE YOU CAN FIND MORE INFORMATION
  We file annual, quarterly
  and other reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet
  at the SEC's website at http://www.sec.gov. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and
  Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish to
  the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act can also be accessed free of charge by linking directly from our website
  at www.alzamend.com. These filings will be available as soon as reasonably practicable after we electronically file such material with,
  or furnish it to, the SEC. Information contained on our website is not part of this prospectus.
  The Registrant hereby undertakes
  to provide without charge to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, upon written
  or oral request of any such person, a copy of any and all of the information that has been incorporated by reference in this prospectus
  but not delivered with the prospectus other than the exhibits to those documents, unless the exhibits are specifically incorporated by
  reference into the information that this prospectus incorporates. Requests for documents should be directed to Alzamend Neuro, Inc., Attention:
  Investor Relations, 3802 Spectrum Boulevard, Suite 112C, Tampa, Florida 33612, (844) 722-6333.
  11
  ALZAMEND NEURO, INC.
  25,950,000 SHARES OF COMMON STOCK
  REOFFER PROSPECTUS
  July 13, 2021
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  Item 3. Incorporation of Documents by Reference.
  The following documents filed
  with the SEC are hereby incorporated by reference in this prospectus (unless otherwise noted, the SEC file number for each of the documents
  listed below is 001-40483):
  ·
  Amendment No. 4 to the Registrant's Registration Statement on Form S-1 filed with the Securities and Exchange Commission on June 11, 2021 (File No. 333-255955), which contains the Registrant's audited financial statements for the latest fiscal year for which such statements have been filed
  ·
  The Registrant's Prospectus filed on June 15, 2021 pursuant to Rule 424(b) under the Securities Act, relating to the Registration Statement on Form S-1, as amended (File No. 333-255955).
  ·
  Current Report on Form 8-K filed on June 22, 2021; and
  ·
  The description of the Registrant's Common Stock which is contained in a registration statement on Form 8-A filed on June 11, 2021 under the Exchange Act, including any amendment or report filed for the purpose of updating such description.
  All documents filed by the
  Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and
  prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been
  sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement
  and to be part hereof from the date of filing of such documents;
  provided
  ,
  however
  , that documents or information
  deemed to have been furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into
  this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall
  be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or
  in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.
  Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration
  Statement.
  Item 4. Description of Securities.
  Not applicable.
  Item 5. Interests of Named Experts and Counsel.
  Not applicable.
  Item 6. Indemnification of Directors and Officers.
  As permitted by Delaware law,
  our certificate of incorporation provides that no director will be liable to us or our stockholders for monetary damages for breach of
  certain fiduciary duties as a director. The effect of this provision is to restrict our rights and the rights of our stockholders in derivative
  suits to recover monetary damages against a director for breach of certain fiduciary duties as a director, except that a director will
  be personally liable for:
  •
  any breach of his or her duty of loyalty to us or our stockholders;
  •
  acts or omissions not in good faith which involve intentional misconduct or a knowing violation of law;
  •
  the payment of dividends or the redemption or purchase of stock in violation of Delaware law; or
  •
  any transaction from which the director derived an improper personal benefit.
  This provision does not affect
  a director's liability under the federal securities laws.
  At present, we do not maintain
  directors' and officers' liability insurance in order to limit the exposure to liability for indemnification of directors
  and officers, including liabilities under the Securities Act; however, we are in the process of obtaining such insurance.
  Insofar as indemnification
  for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant
  pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange
  Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event
  that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a
  director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by
  such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion
  of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
  such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication
  of such issue.
  Item 7. Exemption from Registration Claimed.
  The issuance of the Shares
  being offered by the Form S-3 resale prospectus were deemed to be exempt from registration under the Securities Act in reliance upon Section
  4(a)(2) of the Securities Act (or Regulation D or Regulation S promulgated thereunder), or Rule 701 promulgated under Section 3(b) of
  the Securities Act as transactions by an issuer not involving any public offering or pursuant to benefit plans and contracts relating
  to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions
  to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate
  legends were placed upon the stock certificates issued in these transactions. All recipients had adequate access, through their relationships
  with us, to information about the Registrant.
  Item 8. Exhibits.
  EXHIBIT INDEX
  Incorporated by Reference
  Exhibit
  Number
  Description
  Schedule
  Form
  File
  Number
  Exhibit
  Filing
  Date
  4.1
  Certificate of Incorporation of the Registrant, as currently in effect.
  DOS
  333-251427
  2.1
  August 19, 2016
  4.2
  Amended and Restated Bylaws of the Registrant, as currently in effect.
  S-1
  333-255955
  3.2
  May 10, 2021
  4.3*
  Form of Common Stock certificate of Registrant.
  5.1*
  Opinion of Olshan Frome Wolosky LLP
  23.1*
  Consent of Baker Tilly US, LLP
  23.2*
  Consent of Olshan Frome Wolosky LLP (included in Exhibit 5.1)
  24.1*
  Power of Attorney (included on the signature page of this Form S-8).
  99.1*
  2016 Amended and Restated Stock Incentive Plan
  99.2*
  2021 Stock Incentive Plan
  99.3*
  Form of 2019 Option Grants
  99.4*
  Form of 2021 Option Grants
  *
  Filed herewith.
  Item 9. Undertakings.
  A. The undersigned Registrant hereby undertakes:
  1. To file, during any period
  in which offers or sales are being made, a post-effective amendment to this Registration Statement:
  (i) To include any prospectus
  required by section 10(a)(3) of the Securities Act;
  (ii) To reflect in the
  prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment
  thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement.
  Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered
  would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be
  reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
  and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration
  Fee" table in the effective Registration Statement.
  (iii) To include any
  material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change
  to such information in the Registration Statement;
  Provided, however,
  that
  paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by
  those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of
  the Exchange Act that are incorporated by reference in the Registration Statement.
  2. That, for the purpose
  of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement
  relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide
  offering thereof.
  3. To remove from registration
  by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
  B. The undersigned Registrant hereby undertakes
  that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant
  to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's
  annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall
  be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time
  shall be deemed to be the initial bona fide offering thereof.
  C. Insofar as indemnification for liabilities
  arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing
  provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification
  is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
  against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
  person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
  person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been
  settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
  public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
  SIGNATURES
  Pursuant to the requirements of the Securities
  Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for
  filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in the City of Tampa, State of Florida, on July 13, 2021.
  ALZAMEND NEURO, INC.
  By:
  /s/ STEPHAN JACKMAN
  Stephan Jackman
  Chief Executive Officer (Principal Executive Officer)
  By:
  /s/ LIEN T. ESCALONA
  Lien T. Escalona
  Chief Financial Officer (Principal Financial and Accounting Officer)
  POWER OF ATTORNEY
  KNOW ALL PERSONS BY THESE PRESENTS, that each
  person whose signature appears below hereby constitutes and appoints Stephan Jackman and Henry C.W. Nisser, and each of them, as his true
  and lawful attorneys-in-fact and agents, with full power of substitution, for him in any and all capacities, to sign any or all amendments
  to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto, and
  other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents
  full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as
  fully for all intents and purposes as he might or could do in person, hereby and about the premises hereby ratifying and confirming all
  that said attorneys-in-fact and agent, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof
  Pursuant to the requirements of the Securities
  Act of 1933, as amended, the following persons in the capacities and on the dates indicated have signed this Registration Statement below.
  Signature
  Title
  Date
  /s/ STEPHAN JACKMAN
  Chief Executive Officer (Principal Executive
  Officer) and Director
  July 13, 2021
  Stephan Jackman
  /s/ LIEN T. ESCALONA
  Chief Financial Officer (Principal Financial
  Officer and Principal Accounting Officer)
  July 13, 2021
  Lien T. Escalona
  /s/ WILLIAM B. HORNE
  Chairman of the Board
  July 13, 2021
  William B. Horne
  /s/ HENRY C.W. NISSER
  Director
  July 13, 2021
  Henry C.W. Nisser
  /s/ MARK GUSTAFSON
  Director
  July 13, 2021
  Mark Gustafson
  /s/ LYNNE F. MCGRATH
  Director
  July 13, 2021
  Lynne F. McGrath
  /s/ JEFFREY ORAM
  Director
  July 13, 2021
  Jeffrey Oram
  /s/ ANDREW H. WOO
  Director
  July 13, 2021
  Andrew H. Woo